Zinc finger degradation determinant sequences

By introducing specific amino acid substitutions into the zinc finger degradation determinant system, the sensitivity to IMiD molecules is enhanced, solving the problems of immune response and side effects when existing systems regulate the expression and stability of target proteins at low doses, and achieving safer and more effective protein regulation.

CN118922547APending Publication Date: 2024-11-08STICHTING HET NEDERLANDS KANKER INST ANTONI VAN LEEUWENHOEK ZIEKENHUIS
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202380027768.5
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-03-18
Filing Date
2023-03-17
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

Existing zinc finger degradation determinant systems pose risks of immune-mediated rejection and side effects in clinical applications, especially when using IMiD molecules, where it is difficult to effectively regulate the expression and stability of target proteins at low doses.

Method used

An improved zinc finger degradation determinant sequence was developed to enhance sensitivity to IMiD molecules by introducing specific amino acid substitutions into the heterozygous zinc finger domain, thereby modulating the degradation and stability of target proteins at low concentrations, including the use of degradation determinant tags and peptides containing first and second zinc finger domains.

Benefits of technology

This approach enables effective regulation of target proteins at low IMiD concentrations, reducing the risk of immune responses and side effects, and enhancing the system's clinical application potential.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118922547A_ABST
    Figure CN118922547A_ABST
Patent Text Reader

Abstract

The present invention relates generally to novel zinc finger degradation determinant sequences wherein said zinc finger degradation determinant comprises at least one non-natural zinc finger domain in a hybrid form wherein said zinc finger domain is composed of a first moiety from a first zinc finger and a second moiety from a second zinc finger, preferably a first moiety from a first zinc finger and a second moiety from a second zinc finger. Wherein the first portion comprises a beta-hairpin of a first zinc finger and the second portion comprises an alpha-helix of a second zinc finger. In a preferred embodiment, the degradation determinant tag further comprises a second non-natural hybrid zinc finger domain.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention generally relates to novel zinc finger degron sequences, wherein the zinc finger degron comprises at least one non-natural zinc finger domain in hybrid form, wherein the non-natural zinc finger domain consists of a first portion from a first zinc finger and a second portion from a second zinc finger, preferably, wherein the first portion comprises a β-hairpin of the first zinc finger and the second portion comprises an α-helix of the second zinc finger. In a preferred embodiment, the degron tag further comprises a second non-natural hybrid zinc finger domain. In a preferred embodiment, the zinc finger domain comprises at least two amino acid substitutions. Fusion proteins comprising a degron tag according to the present invention are also provided, as well as the use of a degron tag according to the present invention in methods involving controlling target protein levels, cell activity, expression, etc. Background Art

[0002] The Background Description includes information that may be helpful in understanding the present invention. It is not an admission that any of the information provided herein is prior art or relevant to the presently claimed invention, nor is it an admission that any publication specifically or implicitly referenced is prior art.

[0003] Cell behavior is largely controlled by the expression levels of different proteins, including key regulatory proteins. In order to achieve control over this cell behavior, synthetic or artificial protein stability control tools have been developed that allow reversible and titratable expression of a protein of interest (POI) by exogenously provided factors, such as (small) compounds, e.g., on a time scale of minutes.

[0004] In particular, strategies for controlling the rate of POI proteolysis (i.e., rate of protein degradation, such as intracellular protein degradation) have been developed for exogenously provided factors such as membrane permeable small molecules. Well-known examples include SMASh / Asunaprevir (Chung et al. Nat Chem Biol. 2015 Sep; 11 (9): 713-20), FKBP12F36V / dTAG-13 (Nabet et al. Nat Chem Biol. 2018 May; 14 (5): 431-441), zinc finger degradation determinant / IMiD (Sievers et al. Science. 2018 Nov 2; 362 (6414): eaat0572), and DD / Shield1 (Haugwitz et al. Biotechniques. 2008 Mar; 44 (3): 432-3) platforms.

[0005] These platforms and the principles on which they are based are well known to those skilled in the art and have been extensively described in the scientific and patent literature (see, for example, WO2019007869, WO2020132039, WO2021188286, or WO2021080427 for zinc finger degron / IMiDs).

[0006] Most of these platforms and the methods used therein involve the fusion of a POI to a small molecule-dependent degron domain (i.e., a protein domain or portion that is important in regulating the rate of protein degradation), wherein the preferential interaction of the degron (domain) with the proteasome complex in the presence of a small molecule regulator leads to the subsequent degradation of the POI-degron fusion protein.

[0007] Alternatively, the POI may be fused to a degron domain that is intrinsically unstable and therefore susceptible to proteolysis, and stabilization of the folded protein state by the addition of small molecules is used to prevent such proteolysis.

[0008] The POI may also be fused to a regulatory domain containing a constitutively active degron domain, a protease and a corresponding protease cleavage site in the linker between the POI and the degron tag. In the absence of a protease inhibitor, the degron domain is proteolytically removed from the POI, thereby, for example, stabilizing the expression of the POI. Conversely, in the presence of a protease inhibitor, degradation of the fusion protein is induced.

[0009] Despite the great interest in the development of protein stability control systems that can be used for cell therapy applications, many challenges remain in the future. For example, the preferred protein stability regulators for clinical cell therapy products should be composed of human sequences to minimize the risk of immune-mediated rejection reactions, such as the immunogenicity of the SMASh-tagged degradation determinant system based on the hepatitis C virus (HCV)-derived NS3 / 4A protease (Tan et al, PLoS One. 2017; 12(7): e0181578), which may limit its clinical application.

[0010] In addition, small molecule modulators of protein stability control domains should be safe and preferably clinically approved. The dTAG-13PROTAC for the FKBP12F36V-tag degradation determinant system has not yet been clinically approved, complicating the clinical development of FKBP12F36V-based regulatory systems. In addition, the large size of PROTAC molecules is considered a challenge for the administration and metabolism of such drugs (Hu et al. Chembiochem. 2021 Sep 8. doi: 10.1002 / cbic.202100270. Publicly available online before publication).

[0011] Furthermore, and importantly, small molecule concentrations sufficient to induce biologically meaningful control over protein levels, such as meaningful control over protein degradation (e.g., degradation of a POI fused to a degron), preferably should be compatible with clinical use, particularly in the context of chronic small molecule administration where side effects may be a concern.

[0012] Sievers et al. Science. 2018 Nov 2; 362(6414): eaat0572 describes an immunomodulatory imine drug (IMiD)-inducible zinc finger degradation determinant system that fuses a POI with a short zinc finger degradation determinant tag (sometimes also referred to as a zinc finger domain and / or zinc finger polypeptide) to facilitate recruitment of the POI-zinc finger fusion degradation determinant protein to the IMiD / CRBNE3 ligase complex, for example in the presence of a small molecule known as an IMiD. It is generally believed that IMiDs bind to Cereblon (CRBN), a substrate receptor for the CRL4CRBN E3 ubiquitin ligase, and CRBN can recruit (fusion) proteins containing zinc finger degradation determinants through interactions with zinc finger degradation determinants, which are mediated by IMiDs such as thalidomide and its derivatives. The zinc finger degradation determinant system is based on human protein sequences, thereby limiting the risk of immune-mediated rejection. Furthermore, protein stability is modulated by clinically approved small molecules such as thalidomide, pomalidomide, and lenalidomide (as examples of IMiDs), thus facilitating the clinical development of these systems.

[0013] In preclinical work, this protein stability control system has shown its value in clinically relevant applications, such as the regulation of CAR-T cell activity when this zinc finger degradation determinant is fused to CARs (Jan et al. Sci Transl Med. 2021 Jan 6; 13 (575): eabb6295). In addition, we recently reported the application of the IMiD / zinc finger system in the chemically regulated and SH2-delivered-Inhibitory Tail (CRASH-IT) switch platform, which allows the control of cell activity levels of various cell therapy platforms (such as CAR-T, TCR-T and NK cells) (Sahillioglu et al., WO2021080427).

[0014] Although the fact that zinc finger degradation determinants are composed of human sequences and can be controlled using approved molecules has promoted the clinical application of this system, the clinical use of these IMiD molecules in the treatment of patients with hematological tumors is associated with a large number of side effects at therapeutically effective concentrations. For example, in a study evaluating high (25 mg per day) and low (5 mg per day) doses of lenalidomide for maintenance therapy in patients with multiple myeloma, lenalidomide dose was shown to be associated with both toxicity and efficacy, and dose reductions were common in the high-dose lenalidomide cohort due to toxicity, especially neutropenia. (Fenk et al. Clin Cancer Res. 2020 Nov 15; 26(22): 5879-5886). / pct

[0015] Due to concerns associated with higher dose IMiD use, the identification of novel zinc finger degron sequences that can be regulated at lower drug doses is attractive.

[0016] In view of this, new products, compositions, methods and uses that use improved and novel zinc finger degradation determinant sequences to control the (expression) level of target proteins are highly desirable, but are not currently available. In particular, there is a clear need in the art for reliable, efficient and reproducible products, compositions, methods and uses, for example, in disease treatment or prevention, allowing the use of novel zinc finger degradation determinant sequences (zinc finger degradation determinant tags, domains, polypeptides) to regulate the (expression) level of target proteins in a manner compatible with clinical use, such as allowing the use of reduced concentrations of small molecules (lower drug doses), particularly IMiDs, which regulate the degradation / stability of proteins by interacting with degradation determinant sequences, for example, fused to target proteins. Therefore, the technical problem of the present invention can be seen in providing such products, compositions, methods and uses that meet any of the above requirements. The technical problem is solved by the claims and the embodiments characterized below. Summary of the invention

[0017] The scope of the present invention is defined by the claims. Subject matter not covered by the claims does not constitute a part of the invention claimed for protection. BRIEF DESCRIPTION OF THE DRAWINGS

[0018] Embodiments of the present invention are further described below with reference to the accompanying drawings, in which:

[0019] Figure 1 : The sensitivity of zinc finger degrons to IMiDs can be increased by changing the second zinc finger sequence. (A) Schematic representation of a set of zinc finger degrons comprising a ZFP91 ZF4β hairpin and an IKZF1 ZF2α helix as hybrid first zinc fingers. In this set, the degrons comprise a second zinc finger sequence selected from IKZF1ZF3 (single hybrid dual zinc finger degrons), IKZF1 ZF3β hairpin-ZFP91 ZF5α helix (double hybrid degrons), or the degrons do not comprise a second zinc finger (single hybrid single zinc finger degrons). (BE) Primary human T cells modified with an HLA class I-restricted CDK4 TCR plus a Zap70-PD1-degron CRASH-IT switch, wherein the degron sequence is selected from (A), pretreated with the indicated concentrations of thalidomide. Data show intracellular IFNγ, IL2, TNFα and cell surface LAMP1 expression of CDK4TCR+, EGFP high CD8+ T cells when co-cultured with NKIRTIL006 melanoma cells in the presence of the indicated concentrations of thalidomide. Error bars represent standard deviation (n=2). Data represent two independent experiments.

[0020] Figure 2 : Schematic overview of a non-limiting embodiment according to the present invention.

[0021] Figure 3 : Design of a synthetic zinc finger (SynFinger) library. The SynFinger library contains Zap70-PD1-degradant CRASH-IT switch variants, in which the parent zinc finger degradation determinant contains single or double amino acid substitutions, or no substitutions. This figure depicts the double hybrid degradation determinant sequence used as the parent zinc finger sequence in the SynFinger library screening. The amino acid represented by the arrow is replaced with any other gene-encoded amino acid except cysteine. The two cysteines and the conserved glycine in the ZFP91 ZF4β hairpin, and the two histidines in the IKZF1 ZF2α helix remain constant. The substitution mutations are numbered starting from the first amino acid of the ZFP91 ZF4β hairpin (marked with an asterisk).

[0022] Figure 4 : Enrichment of certain amino acid substitutions in the top 100 degrons. After removing SynFingers with low sequence reads, SynFinger degrons were ranked according to enrichment index (EI) values ​​(see Examples). The figure depicts the number of times each amino acid substitution was found in combination with other amino acid substitutions in the top 100 SynFinger degrons. For example, in the top 100 SynFingers, the Q12R mutation was observed in 11 double amino acid substitution combinations, together with any one of K13T, L17M, K13V, E4L, L17Y, L22H, C10A, I20R, N15S, E4W, and E4Q.

[0023] Figure 5 SynFinger fusion proteins enable sensitive control of immune cell function. SynFinger subsets identified in SynFinger library screening were validated separately. (AH) Primary human T cells were modified with an HLA class I restricted CDK4TCR plus a Zap70-Siglec11-degrader CRASH-IT switch, where the degrader sequence contained the parent zinc finger degrader ( Figure 1 and 3Figure 2 shows a double hybrid degradation determinant (shown in Figure 2 ), or a parent zinc finger degradation determinant with the following mutations: G14N / K21A, G14M / N15R, L17I / K21L, E4R / Q12L, Q12R / K13T or Q12R / K13V. Primary human T cells modified with an HLA class I restricted CDK4 TCR+ vector control were used as controls. Cells were pretreated or not treated with 5nM lenalidomide. The data depict the expression of intracellular IFNγ, IL2, TNFα and cell surface LAMP1 in CDK4 TCR+, EGFP intermediate CD8+ T cells after co-culture with NKIRTIL006 melanoma cells in the continuous absence (EH) or continuous presence (AD) of 5nM lenalidomide. The dotted horizontal lines indicate the cytokine production and degranulation levels of cells modified with the CRASH-IT switch containing the parent zinc finger degradation determinant. Error bars represent standard deviations (n=2). SynFinger and vehicle control groups were compared to the parental zinc finger group using a one-sided t-test: * = p < 0.05, ** = p < 0.01, *** = p < 0.001, **** = p < 0.0001, ns = not significant. Data are representative of two independent experiments.

[0024] Figure 6 : SynFinger containing a CRASH-IT switch enables restoration of cytokine production and degranulation at lower IMiD concentrations compared to zinc finger degradation determinants not of the present invention. (AD) Primary human T cells modified with HLA class I restricted CDK4TCR plus Zap70-Siglec11-degrader CRASH-IT switch were pretreated with or without the indicated concentrations of lenalidomide, wherein the degradation determinant sequence comprises a prior art zinc finger degradation determinant (e.g. Figure 1 The single hybrid dual zinc finger degron shown), the parent zinc finger degron (as shown Figure 1 and 3 (A) shows the expression of intracellular IFNγ, IL2, TNFα, and cell surface LAMP1 in CDK4 TCR+, EGFP intermediate CD8+ T cells co-cultured with NKIRTIL006 melanoma cells in the presence or absence of the indicated concentrations of lenalidomide (AD). Error bars indicate standard deviation (n=3). Data are representative of two independent experiments. (E) shows the EC50 lenalidomide (nM) values ​​for cells in (AD) and the EC50 fold change between the prior art zinc finger degraders and SynFinger containing Q12R / K13V substitutions.

[0025] Figure 7 : Combination of double substitution sets can further improve the lenalidomide sensitivity of SynFinger degron. (AD) Primary human T cells modified with HLA class I-restricted CDK4 TCR plus Zap70-Siglec11-degron CRASH-IT switch were pretreated or left untreated with the indicated concentrations of lenalidomide, where the degron sequence contained the parent zinc finger degron ( Figure 1 and 3 The double hybrid degradation determinant shown in ), or the parent zinc finger degradation determinant with the following mutations: G14N / K21A, Q12R / K13V or Q12R / K13V / G14N / K21A. The data show the expression of intracellular IFNγ, IL2, TNFα and cell surface LAMP1 of CDK4 TCR+, EGFP intermediate, CD8+ T cells when co-cultured with NKIRTIL006 melanoma cells in the continuous presence or absence of the specified concentration of lenalidomide (AD). Error bars represent standard deviation (n=3). The data represent two independent experiments.

[0026] definition

[0027] A portion of this disclosure contains material that is subject to copyright protection (such as, but not limited to, diagrams, photographs of devices, or any other aspect of this disclosure that may be copyrighted in any jurisdiction). The copyright owner has no objection to the facsimile reproduction by anyone of the patent document or the patent disclosure, as it appears in the Office patent file or records, but otherwise reserves all copyright rights whatsoever.

[0028] Various terms related to the method, composition, purposes and other aspects of the present invention are used in various places in the specification and claims. Unless otherwise stated, these terms have the ordinary meaning in the field to which the present invention belongs. Other clearly defined terms should be interpreted in a manner consistent with the definition provided herein. Although any method and material similar or equivalent to that described herein can be used in practice to test the present invention, preferred materials and methods are described herein. For purposes of the present invention, the following terms are defined below.

[0029] As used herein, the singular terms "a," "an," and "the" include plural terms unless the context clearly dictates otherwise. Thus, for example, reference to "a degron tag" includes two or combinations of degron tags, and so forth. For example, a method of administering a drug or fusion protein includes administering a plurality of molecules (e.g., 10, 100, 1000, tens of thousands, hundreds of thousands, millions, or more molecules).

[0030] As used herein, "about" and "approximately" with respect to measurable values ​​of a quantity, duration, etc., are meant to encompass variations of ±20% or ±10%, more preferably ±5%, even more preferably ±1%, and still more preferably ±0.1% relative to the stated value, as such variations are suitable for performing the disclosed invention.

[0031] As used herein, “and / or” refers to a situation in which one or more of the stated conditions occur alone or in combination with at least one of the stated conditions, until all of the stated conditions occur.

[0032] As used herein, "at least" a particular value means the particular value or more. For example, "at least 2" is understood to be the same as "2 or more", i.e., 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 ..., etc. As used herein, the term "at most" a particular value means the particular value or less. For example, "at most 5" is understood to be the same as "5 or less", i.e., 5, 4, 3, .... -10, -11, etc.

[0033] As used herein, "comprising" or "comprises" is interpreted as being inclusive and open-ended, rather than exclusive. Specifically, the term and its variants refer to the inclusion of specified features, steps, or components. These terms should not be interpreted as excluding the presence of other features, steps, or components. It also includes the more restrictive "consisting of..."

[0034] As used herein, "conventional techniques" or "methods known to the skilled person" refer to the situation where the methods of performing the conventional techniques used in the methods of the present invention are obvious to the skilled person. The practice of conventional techniques in molecular biology, biochemistry, cell culture, genomics, sequencing, medical treatment, pharmacology, immunology and related fields is well known to those skilled in the art and is discussed in various manuals and literature references.

[0035] As used herein, "exemplary" or "for example" means serving as an "example, instance, or illustration" and should not be construed to exclude other configurations, including those disclosed herein.

[0036] In the context of the present invention, when there are differences between the sequences disclosed in the description and the sequences in the sequence listing, the sequences indicated in the description prevail, unless there is a clear other intention. Wherein, in a preferred embodiment, reference is made to proteins or parts thereof, these relate to human proteins or parts thereof.

[0037] In the present disclosure, various aspects of the present invention may be presented in the format of a range. It should be understood that the description of the range format is only for convenience and should not be interpreted as a limitation on the scope of the present invention. The description of the range should be regarded as having clearly disclosed all possible sub-ranges and single values ​​within the range, including integers and non-integers. For example, the description of a range, such as from 1 to 6, should be considered to specifically disclose sub-ranges, such as from 1 to 3, from 1 to 4, from 1 to 5, from 2 to 4, from 2 to 6, from 3 to 6, etc., and single numbers within the range, such as 1, 2, 2.7, 3, 4, 5, 5.3, 6, etc. This applies regardless of the width of the range.

[0038] As used herein, the term "fusion protein" refers to any polypeptide that does not normally occur in nature, being a species, in particular a polypeptide in which one or more parts of the amino acid sequence are not associated with each other in nature. For example, a fusion protein may comprise an N-terminal part consisting of a first amino acid sequence and a C-terminal part consisting of a second amino acid sequence that is not associated with each other in nature and / or is not associated with each other in this order in nature. For example, a fusion protein may be obtained from the transcription and translation of a nucleic acid fusion gene. Such a fusion gene may be produced by connecting parts of two different genes / nucleic acid sequences. In the context of the present invention, a fusion protein may comprise a degron tag according to the invention or a hybrid zinc finger polypeptide according to the invention fused to a target protein.

[0039] As used herein, the term "host cell" refers to a cell into which exogenous nucleic acids (polynucleotides) and / or exogenous polypeptides have been introduced, including progeny of such cells. Host cells may include "transformants" and "transformed cells," which include primary transformed cells and progeny cells derived therefrom, without regard to the number of passages. The nucleic acid content of progeny cells may not be exactly the same as that of the parental cells, but may contain mutations. Mutant progeny having the same function or biological activity as the initially transformed cells screened or selected are included herein. Host cells include in vitro host cells and in vivo host cells.

[0040] As used herein, "immunomodulatory drugs", "immunomodulatory imide drugs" or "IMiDs" refer to compounds known in the art. IMiDs include thalidomide, pomalidomide, lenalidomide, iberdomide (CC-220), avadomide (CC-122) and CC-885, or pharmaceutically acceptable salts thereof; these compounds may also be referred to as cereblon modulators (CRBN modulators). Thalidomide, lenalidomide and pomalidomide have all been approved for the treatment of various diseases, while other IMiDs or cereblon modulators are under review. The compound may be in the form of a free acid or free base, or a pharmaceutically acceptable salt.

[0041] As used herein, "in vivo" refers to an event that occurs within a subject's body, and "in vitro" refers to an event that occurs outside a subject's body. For example, an in vitro assay or method includes any assay or method performed outside a subject. In vitro assays or methods include cell-based assays, in which living or dead cells are used. In vitro assays also include cell-free assays, in which intact cells are not used.

[0042] As used herein, the term "isolated" refers to a protein or nucleic acid present in a non-naturally occurring environment, such as separated from its naturally occurring environment. For example, a protein or polypeptide separated according to the present invention refers to a protein that is no longer in its natural environment, such as in vitro or in a recombinant host cell. The term refers to the artificial or synthetic production of such a protein or nucleic acid, in addition to being separated from a naturally occurring source. In the context of the present invention, it will be clear to the skilled person that reference to a protein, polypeptide, polynucleotide includes reference to an "isolated" protein, polypeptide, nucleic acid or polynucleotide.

[0043] As used herein, the term "linker" when referring to a portion of a protein refers to a stretch of amino acids that connects two portions of a protein together, such as in a fusion protein. Generally, such molecules have no specific biological activity other than connecting or maintaining a minimum distance or other spatial relationship between proteins. However, in certain embodiments, the linker can be selected to affect certain properties of the linker and / or protein, such as the folding, net charge, or hydrophobicity of the linker.

[0044] As used herein, the term "non-natural" refers to a polypeptide, polynucleotide or domain that is not present in nature and is contained in such a polypeptide or polynucleotide, for example, is known not to exist in (human) cells, i.e., wherein one or more parts of the polypeptide, or polynucleotide or domain are not associated with each other in nature. An example is a fusion protein as defined herein. As explained herein, in particular, the term "non-natural" refers to the fact that the first hybrid zinc finger domain is composed of a first part and a second part, wherein the first part is obtained from a first Cys2-His2 zinc finger domain and the second part is obtained from a second Cys2-His2 zinc finger domain, wherein the first and second Cys2-His2 zinc finger domains are different from each other. Therefore, the non-natural first hybrid zinc finger domain is a fusion protein composed of the first part and the second part. Alternatively, the non-natural first hybrid zinc finger domain can therefore be referred to as the first hybrid zinc finger domain. As the skilled person will understand, the same analogy also applies to the term "non-natural second hybrid zinc finger domain", which can therefore also be referred to as "second hybrid zinc finger domain".

[0045] As used herein, the term "nucleic acid" or "polynucleotide" refers to any polymer or oligomer of (contiguous) nucleotides. Nucleic acids can be DNA or RNA, or a mixture thereof, and can exist permanently or transiently in single-stranded or double-stranded forms, including homoduplexes, heteroduplexes, and hybrid states.

[0046] As used herein, the term "pharmaceutical composition" refers to a composition formulated into a pharmaceutically acceptable or physiologically acceptable composition for administration to a cell or subject. The composition of the present invention may also be administered in combination with other agents, provided that the additional agents do not adversely affect the ability of the composition to deliver the intended therapy. In addition to the pharmaceutically active agent, the pharmaceutical composition generally also comprises one or more pharmaceutically acceptable carriers (or excipients). The pharmaceutical composition is specially formulated to be administered in solid or liquid form, including those suitable for the following: (1) oral administration, such as an immersion (aqueous or non-aqueous solution or suspension), tablets, boluses, powders, granules, pastes; (2) parenteral administration, such as subcutaneous, intramuscular or intravenous injection, such as a sterile solution or suspension; (3) topical application, such as application to the skin as a cream, ointment or spray; (4) intravaginal or intrarectal, such as a pessary, cream or foam; or (5) aerosol, for example, as an aqueous aerosol, liposomal preparation or solid particles containing the compound. Medicines, therapeutic agents, medicaments and pharmaceutical compositions according to the present invention can be formulated to be administered by a variety of routes including but not limited to parenteral, intravenous, intra-arterial, intramuscular, intratumoral and oral administration. Medicines, therapeutic agents, medicaments and compositions can be formulated in liquid or solid form. Liquid preparations can be formulated for administration to selected areas of human or animal bodies by injection.

[0047] As used herein, "protein" or "polypeptide" are used interchangeably to refer to a molecule consisting of a chain of amino acids without reference to a specific mode of action, size, three-dimensional structure or origin. Therefore, a "fragment" or "portion" or "domain" of a protein may still be referred to as a "protein". The protein as defined herein and used in any method defined herein may be an isolated protein, a native protein or a non-native protein. An "isolated protein" refers to a protein that is no longer in its natural environment, such as in vitro or in a recombinant bacterial or plant host cell. In a specific embodiment of the present invention, the protein is a protein that is involved in regulating cell behavior, particularly a protein that can regulate cell behavior in the context of treating a disease. In other words, the term "portion" or "domain" refers to an amino acid sequence that is less than the full-length protein sequence of any protein described herein. The term "domain" is also used more specifically herein to refer to functional domains known in the art, such as zinc finger domains, extracellular domains, intracellular domains, signaling domains, intracellular signaling domains, cytoplasmic domains, and transmembrane domains.

[0048] As used herein, "sequence" or "nucleotide sequence" may refer to the order of nucleotides of a nucleic acid or nucleotides within a nucleic acid. In other words, any order of nucleotides in a nucleic acid may be referred to as a sequence or nucleotide sequence. The term "amino acid sequence" refers to the order of amino acids of a polypeptide or the order of amino acids within a polypeptide (or protein). In other words, any order of amino acids in a polypeptide may be referred to as a sequence or amino acid sequence.

[0049] As used herein, "subject" refers to an organism to be treated, e.g., an organism to which administration is contemplated. According to the present invention, a subject can be any subject, including but not limited to humans, men, women, infants, children, teenagers, adults, young adults, middle-aged or elderly persons, and / or other primates or mammals. Preferably, the subject is a human patient. The subject may have been diagnosed with cancer or is suspected of having cancer.

[0050] As used herein, "treatment," "treating," "mitigation," "alleviation," and "amelioration," in the context of a subject to be treated, all refer to an approach for obtaining beneficial or desired results, including, but not limited to, a therapeutic benefit. A therapeutic benefit refers to eradication or amelioration of the underlying condition being treated. Additionally, a therapeutic benefit is achieved by eradication or amelioration of one or more physiological symptoms associated with the underlying condition, such that an improvement is observed in the patient, although the patient may still be afflicted with the underlying condition.

[0051] As used herein, the terms "construct", "nucleic acid construct", "vector" and "expression vector" are used interchangeably and are defined as artificial nucleic acid molecules produced using recombinant DNA technology. Thus, constructs and vectors do not include naturally occurring nucleic acid molecules, although nucleic acid constructs may contain (part of) naturally occurring nucleic acid molecules.

[0052] Detailed description

[0053] The invention is defined herein and more particularly in the claims appended hereto.

[0054] It is contemplated that any method, use or composition described herein may be implemented with respect to any other method, use or composition described herein. The embodiments discussed in the context of the methods, uses and / or compositions of the present invention may be used with respect to any other method, use or composition described herein. Therefore, embodiments associated with a method, use or composition may also be applied to other methods, uses and compositions of the present invention.

[0055] Any reference in this specification to a method of treatment also refers to the compounds, pharmaceutical compositions and medicaments of the invention for use in a method of treating the human (or animal) body by therapy.

[0056] The present invention provides compositions comprising degron tags and / or hybrid zinc finger polypeptides, and methods for regulating protein abundance in a target-specific manner by using degron tags and / or hybrid zinc finger polypeptides.

[0057] The present invention can target endogenous and exogenous (e.g., therapeutic) proteins. As disclosed herein, a degradation determinant tag and / or a hybrid zinc finger polypeptide is a peptide that, when fused to a target protein of interest (POI), can convert the POI into a substrate for cereblon (CRBN)-dependent ubiquitination and degradation, which is induced by the administration of immunomodulatory drugs (IMiDs). Without being bound by any theory, it is believed that IMiDs bind to cereblon to form a complex with binding specificity for the degradation determinant tag and / or the hybrid zinc finger polypeptide. Therefore, the fusion protein with the POI becomes a substrate for cereblon-dependent ubiquitination and degradation. Therefore, the degradation determinant tag and / or the hybrid zinc finger polypeptide of the present invention can be used for the targeted degradation of POIs.

[0058] As embodied and broadly described herein, the present invention is directed to the unexpected discovery that zinc finger degrons and / or zinc finger polypeptides can be provided and that exhibit enhanced sensitivity to small molecules, particularly to IMiDs such as those disclosed herein, which modulate protein degradation / stability through interaction with these degrons and / or polypeptide sequences.

[0059] Thus, zinc finger degrons and / or zinc finger polypeptides according to the invention allow the use of lower concentrations of these small molecules, in particular IMiDs, to control protein degradation, expression and / or stability of a protein of interest (and thus, for example, the cellular activity (total activity in a cell) of the protein of interest; e.g., fused to a degron tag, zinc finger degron and / or zinc finger polypeptide according to the invention.

[0060] Therefore, the zinc finger degron (degron tag) and / or zinc finger polypeptide according to the present invention can better control the degradation, expression and / or stability of the target protein (for example, contained in the fusion protein comprising the target protein and the zinc finger degron or zinc finger polypeptide according to the present invention) at similar or reduced concentrations of small molecules, especially IMiDs. At the same time, the degradation, expression, level and / or stability of POI can be regulated more sensitively.

[0061] In other words, and in embodiments of the present invention, the zinc finger degrons (degron tags) and / or zinc finger polypeptides according to the present invention allow for controlling the level (expression) of a target protein, e.g., in a cell or subject, by modulating the degradation and / or stability of the target protein at similar or reduced concentrations of small molecules, in particular IMiDs, which modulate protein degradation / stability by interacting with these degrons and / or polypeptide sequences.

[0062] As will be apparent from the present disclosure, it was unexpectedly found, for example, that improved zinc finger degrons and / or zinc finger polypeptides according to the present invention can be obtained by providing a degron tag and / or polypeptide comprising a first and a second zinc finger domain, wherein each zinc finger domain typically comprises a β-hairpin obtained from a first Cys2-His2 zinc finger domain (also sometimes referred to as the "first" or "third" part in the context of the present invention) and an α-helix obtained from a second Cys2-His2 zinc finger domain (also sometimes referred to as the "second" or "fourth" part in the context of the present invention).

[0063] In particular, it is found that the first zinc finger domain is a hybrid zinc finger domain, that is, the first zinc finger domain is composed of a first part and a second part that do not exist together in nature (non-natural). For example, the first zinc finger domain is a non-natural hybrid zinc finger domain obtained by combining a beta hairpin from a first Cys2-His2 zinc finger domain and an alpha helix from a second Cys2-His2 zinc finger domain, wherein the first and second Cys2-His2 zinc finger domains are not identical or identical.

[0064] Regarding the second zinc finger domain, it was unexpectedly found that, preferably, the second zinc finger domain comprised by the zinc finger degron and / or zinc finger polypeptide according to the present invention is also a hybrid zinc finger domain, such as the first hybrid zinc finger domain described above. The second hybrid zinc finger domain may be the same as or different from the first hybrid zinc finger domain. Preferably, the second hybrid zinc finger domain is different from the first hybrid zinc finger domain.

[0065] At the same time, it was unexpectedly found that when the first hybrid zinc finger domain contained in the zinc finger degron of the present invention and / or the first hybrid zinc finger domain contained in the zinc finger polypeptide according to the present invention further comprises at least two amino acid substitutions as disclosed in detail herein, the sensitivity of the zinc finger degron of the present invention (degron tag) and / or the zinc finger polypeptide of the present invention to small molecules, especially IMiDs, which regulate protein degradation / stability by interacting with these degron and / or polypeptide sequences is further improved.

[0066] In summary, it was unexpectedly found that by providing a non-natural hybrid zinc finger polypeptide comprising a first hybrid zinc finger domain (as defined herein) and comprising at least two amino acid substitutions, improved zinc finger domains and degrons (e.g., degron tags) can be provided. In a preferred embodiment, wherein the hybrid zinc finger polypeptide preferably comprises (as the first hybrid zinc finger domain) in a degron tag according to the present invention, the degron tag according to the present invention comprises two non-natural hybrid zinc finger domains (see Figure 2 ).

[0067] In the context of the present invention, a degron signature according to the present invention may also be referred to as a "bi-hybrid degron".

[0068] In the context of the present invention, a degron comprising a first hybrid zinc finger domain and a second non-hybrid zinc finger domain may also be referred to as a "single hybrid dual zinc finger degron".

[0069] In the present invention, a degron tag comprising a first hybrid zinc finger domain and not comprising a second zinc finger domain may also be referred to as a "single hybrid single zinc finger degron".

[0070] In certain embodiments, the non-natural hybrid zinc finger polypeptide according to the invention is such a "single hybrid single zinc finger degron" comprising two amino acid substitutions as described herein. In embodiments, wherein the non-natural hybrid zinc finger polypeptide according to the invention comprises, in addition to the first hybrid zinc finger domain, a second non-hybrid zinc finger domain, such a molecule may also be referred to as a single hybrid double zinc finger degron, comprising at least two amino acid substitutions as described herein. In embodiments, wherein the non-natural hybrid zinc finger polypeptide according to the invention comprises, in addition to the first hybrid zinc finger domain, a second hybrid zinc finger domain, such a molecule may also be referred to as a "double hybrid degron", comprising at least two amino acid substitutions as described herein.

[0071] As disclosed herein, according to the present invention, and according to a first aspect, there is provided a degron tag comprising a (non-natural) first hybrid zinc finger domain and a (non-natural) second hybrid zinc finger domain, wherein

[0072] (1) the first hybrid zinc finger domain comprises a first part and a second part;

[0073] (2) The first part contains the amino acid sequence X1X2C3X4X5C6X7X8X9X 10 X 11 , wherein X represents any amino acid of the first Cys2-His2 zinc finger domain;

[0074] (3) The second part contains the amino acid sequence X 12 X 13X 14 X 15 X 16 X 17 X 18 H 19 X 20 X 21 X 22 H 23 , wherein X represents any amino acid of a second Cys2-His2 zinc finger domain, wherein the second Cys2-His2 zinc finger domain is different from the first Cys2-His2 zinc finger domain;

[0075] (4) the second portion is C-terminal relative to the first portion;

[0076] (5) the second hybrid zinc finger domain is C-terminal relative to the first hybrid zinc finger domain;

[0077] (6) the second hybrid zinc finger domain comprises a third portion and a fourth portion;

[0078] (7) The third part includes the amino acid sequence (Z)2C(Z)2C(Z) 5-6 , wherein Z represents any amino acid of the third Cys2-His2 zinc finger domain;

[0079] (8) The fourth second part comprises the amino acid sequence (Z)6H(Z) 3-4 H, wherein Z represents any amino acid of a fourth Cys2-His2 zinc finger domain, wherein the fourth Cys2-His2 zinc finger domain is different from the third Cys2-His2 zinc finger domain; and

[0080] (9) the fourth portion is C-terminal relative to the third portion; and

[0081] (10) wherein the first hybrid zinc finger domain comprises at least two amino acid substitutions, wherein the amino acid substitution in the first portion of the first hybrid zinc finger domain is relative to the first portion of the first Cys2-His2 zinc finger domain, and wherein the amino acid substitution in the second portion of the first hybrid zinc finger domain is relative to the second portion of the second Cys2-His2 zinc finger domain, wherein the substitution is not located at C3, C6, X7, H 19 or H 23 Any position in .

[0082] The present invention provides a system comprising a zinc finger degron, which is also referred to herein as a degron tag. Typically, a degron or degron tag is a peptide sequence or protein element that is involved in regulating the degradation rate of a protein, such as a degron or degron tag. In certain embodiments, a degron tag according to the present invention comprises two zinc finger domains. In the context of the present invention, the term zinc finger domain is well understood by a skilled person. Therefore, in an embodiment, a degron is a zinc finger degron that comprises at least two zinc finger domains and can be controlled by an IMiD (e.g., thalidomide, lenalidomide, pomalidomide and / or its analogs). Preferably, the degron tag is capable of promoting or controlling the degradation of a POI, for example when fused to a degron tag in the presence of such an IMiD. Preferably, one or two hybrid zinc finger domains in a degron tag according to the present invention are non-natural hybrid zinc fingers.

[0083] The first hybrid zinc finger domain included in the degradation determinant tag according to the present invention comprises a first part and a second part. The first part and the second part are each independently composed of an amino acid sequence. The first part and the second part contained in the first hybrid zinc finger domain may be directly adjacent to each other, or may not be directly adjacent to each other. In some embodiments, the first part and the second part are connected by a linker peptide, for example, the linker peptide is 1, 2, 3, 4, 5 or more amino acids. Therefore, in some embodiments, the first part and the second part can be connected to each other by an additional linker peptide, for example, the additional linker peptide comprises 1, 2, 3, 4, 5, 6, 7 or more amino acids. However, in some embodiments, there is no additional linker peptide between the first part of the first hybrid zinc finger domain and the second part of the first hybrid zinc finger domain. In this embodiment, the first and second parts are directly adjacent to each other. Preferably, the first and second parts are directly adjacent to each other.

[0084] The first portion of the first hybrid zinc finger domain can be N-terminal or can be C-terminal from the second portion of the first hybrid zinc finger domain. In a preferred embodiment, the first portion of the first hybrid zinc finger domain is N-terminal to the second portion of the first hybrid zinc finger domain.

[0085] In a preferred embodiment, the first portion consists of 8-30 amino acids, with increasing preference for 11-30, 10-20, 11-20, 10-14, 11-14, 10-11, and most preferably 11 amino acids.

[0086] In a preferred embodiment, the second portion consists of 8-30 amino acids, with increasing preference for 12-30, 11-20, 12-20, 11-14, 12-14, and most preferably 12 amino acids.

[0087] In some embodiments, the first non-natural hybrid zinc finger domain is preferably composed of about 16-60 amino acids, preferably about 20-36 amino acids, about 20-30 amino acids, such as 20, 21, 22, 23, 24, 25, 26, 27, 28, 29 or 30 amino acids. In a specific embodiment, the first hybrid zinc finger domain comprises a Cys2 His2 (C2H2) domain, and wherein the hybrid zinc finger domain comprises at least two subdomains (referred to as parts in the present invention), and wherein each subdomain is from a different wild-type zinc finger. For example, wherein the first part of the first hybrid zinc finger domain is from a first wild-type zinc finger, wherein the second part of the first hybrid zinc finger domain is from a different second wild-type zinc finger domain. Based on the present invention, the technician is fully capable of selecting the first part of the first hybrid zinc finger domain from the first wild-type zinc finger and / or is fully capable of selecting the second part of the first hybrid zinc finger domain from the second wild-type zinc finger. For example, he can suitably select such a part from a wild-type zinc finger domain (in particular a wild-type Cys2-His2 (C2H2) zinc finger domain), which can be obtained from various scientific publications and public and well-known gene and protein databases, such as (Sievers et al. Science. 2018 Nov 2; 362 (6414): eaat0572), and, for example, known or expected to destabilize a protein (e.g., a wild-type protein comprising such a wild-type zinc finger domain) in the presence of an IMiD such as thalidomide, and may control the degradation of such a protein. With regard to the second zinc finger, in certain embodiments, the second hybrid zinc finger and / or the third part or the fourth part as described herein may or may not be sensitive to IMiDs by themselves (i.e., in the absence of the first hybrid zinc finger domain), i.e., may or may not be stable in the presence of an IMiD (e.g., thalidomide), and may therefore control the degradation of such a protein. Preferably, it is itself insensitive to IMiDs.

[0088] In certain embodiments, the first portion of the first hybrid zinc finger domain comprises the sequence X1X2C3X4X5C6X7X8X9X 10 X 11The amino acid sequence represented by (X)2C(X)2C(X)5 is a sequence in which each X (X1, X2, ..., etc.) independently represents any amino acid, more specifically, each X represents any natural or proteinogenic amino acid (e.g., alanine, arginine, asparagine, aspartic acid, cysteine, glutamic acid, glutamine, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine and valine). Another way to represent the amino acid sequence contained in the first part of the first hybrid zinc finger domain is (X)2C(X)2C(X)5. However, since amino acid substitutions at specific positions in the first part of the first hybrid zinc finger domain are part of the present invention, it is preferred to use X1X2C3X4X5C6X7X8X9X 10 X 11 , representing individual amino acids and their positions.

[0089] For example, the skilled person will appreciate that X1 may represent another amino acid other than X2, or the same amino acid as X2, for example. The skilled person will appreciate that C3 represents the presence of cysteine ​​at position 3 in the amino acid sequence contained in the first portion of the first hybrid zinc finger domain. Similarly, C6 represents the presence of cysteine ​​at position 6. In a preferred embodiment, the first portion of the first hybrid zinc finger domain has the above amino acid sequence (X1X2C3X4X5C6X7X8X9X 10 X 11 ), wherein the amino acid sequence is a first Cys2-His2 zinc finger domain (e.g., a wild-type Cys2-His2 zinc finger domain). In certain embodiments, the amino acid sequence of the first portion of the first hybrid zinc finger domain may include an additional short chain of amino acids N-terminal thereof, such as 1-10, preferably 1-5, such as 1, 2, 3, 4 or 5 amino acids, such as the first or second Cys2-His2 zinc finger domain. For example, Figure 3 An example of a degron tag according to the invention is provided (with the positions of the amino acid substitutions indicated) in which the N-terminus of the first hybrid zinc finger domain has a short stretch of amino acids GERP (derived from IKZF1 in this case; in certain other embodiments, the stretch may be from another wild-type zinc finger domain, such as GEKP). Experiments have demonstrated that, although the shorter stretch may be included, it does not substantially affect the results obtained with the degron tag (and / or the hybrid zinc finger polypeptide according to the invention).

[0090] As described in detail elsewhere herein, according to the first hybrid zinc finger domain comprised in the degradation determinant tag of the present invention, in a preferred embodiment, the hybrid zinc finger comprises a Cys2 His2 (C2H2) zinc finger domain, and wherein the hybrid zinc finger domain comprises at least two subdomains, namely a first part and a second part, wherein the amino acid sequence of the first part is derived from a wild-type zinc finger, more particularly a wild-type Cys2 His2 (C2H2) zinc finger.

[0091] In a specific embodiment, the second portion of the first hybrid zinc finger domain comprises the sequence X 12 X 13 X 14 X 15 X 16 X17X 18 H 19 X 20 X 21 X 22 H 23 The amino acid sequence represented by 12 , X 13 , ... etc.) independently represent any amino acid, more specifically, wherein each X represents any natural or proteinogenic amino acid (e.g., alanine, arginine, asparagine, aspartic acid, cysteine, glutamic acid, glutamine, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine and valine). Another way to represent the amino acid sequence contained in the second portion of the first hybrid zinc finger domain is (X)7H(X)3H. However, since amino acid substitutions at specific positions in the second portion of the first hybrid zinc finger domain are part of the present invention, it is preferred to use X 12 X 13 X14X 15 X 16 X 17 X 18 H 19 X 20 X 21 X 22 H 23 , represents a single amino acid and its position. In some embodiments, it is also contemplated that the second portion of the first hybrid zinc finger domain is (X)6H(X)3H.

[0092] For example, the skilled person will understand that, for example, X 12 Can represent, for example, X 13 Another amino acid other than H, or it may represent the same amino acid. The skilled person understands that H 19 indicates that there is a histidine at position 19 of the amino acid sequence contained in the second portion of the first hybrid zinc finger domain.23 In a preferred embodiment, the second portion of the first hybrid zinc finger domain has the above amino acid sequence (X 12 X 13 X 14 X 15 X 16 X17X 18 H 19 X 20 X 21 X 22 H 23 ), wherein the amino acid sequence is the second Cys2-His2 zinc finger domain.

[0093] In certain embodiments, the amino acid sequence of the second portion of the first hybrid zinc finger domain may include an additional short stretch of amino acids C-terminal to it, such as, for example, 1-10, preferably 1-5, such as 1, 2, 3, 4 or 5 amino acids of the second Cys2-His2 zinc finger domain. In a preferred embodiment, the first portion of the first hybrid zinc finger domain is the N-terminal end of the second portion from the first hybrid zinc finger domain. In such an embodiment, the second portion is C-terminal relative to the first portion.

[0094] In other words, the first hybrid zinc finger domain comprised in the degron tag according to the present invention is in a preferred embodiment a hybrid zinc finger domain comprising a Cys2 His2 (C2H2) domain, wherein the hybrid zinc finger domain comprises at least two subdomains, i.e. a first part and a second part, and wherein the amino acid sequence of the first part is derived from a wild-type zinc finger, more specifically a wild-type Cys2 His2 (C2H2) zinc finger (i.e. a first Cys2-His2 zinc finger domain), wherein the amino acid sequence of the second part is derived from a wild-type zinc finger, more specifically a wild-type Cys2 His2 (C2H2) zinc finger (i.e. a second Cys2-His2 zinc finger domain), and wherein, preferably, the second Cys2-His2 zinc finger domain is different from the first Cys2-His2 zinc finger domain (e.g., wherein the first Cys2-His2 zinc finger domain is a wild-type zinc finger different from the second Cys2-His2 zinc finger domain). Preferably, the amino acid sequence of the first part comprises or is X1X2C3X4X5C6X7X8X9X 10 X 11 and / or the amino acid sequence of the second part comprises or is X 12 X 13 X 14 X 15 X 16 X 17 X 18 H 19 X20 X 21 X 22 H 23 .

[0095] As described above, the first part and the second part together constitute a first hybrid zinc finger domain, wherein the first part is preferably a first Cys2-His2 zinc finger domain, for example, a wild-type naturally occurring Cys2-His2 zinc finger domain; the second part is preferably a second different Cys2-His2 zinc finger domain, for example, a different wild-type naturally occurring Cys2-His2 zinc finger domain. In such an embodiment, the first hybrid zinc finger domain formed by the first part and the second part can be referred to as a hybrid Cys2-His2 (C2H2) zinc finger domain, for example, a Cys2-His2 zinc finger domain that does not exist in wild-type zinc finger proteins and / or nature.

[0096] The C2H2 zinc finger domain structure has been found to be an important determinant of binding, and may even be a more important determinant than the primary amino acid sequence of the zinc finger domain (see, e.g., Sievers et al. Science. 2018 Nov 2; 362(6414): eaat0572). The C2H2 zinc finger domain is known to mediate binding to the ubiquitin ligase CRL4. CRBN cyclic motifs for drug-dependent (such as IMiDs) interactions (see, for example, An et al, Nat Commun. 8: 15398 (2017), doi: 10.1038 / ncommsl5398, Koduri et al, PNAS 116 (7) 2539-2544 (2019), doi: 10.1073 / pnas.l818109116, WO2019089592, WO2020132039, WO2021188286 or WO202108042).

[0097] Typically, a C2H2 zinc finger domain, including, for example, a first hybrid zinc finger domain and / or a second (hybrid) zinc finger domain according to the present invention, comprises a β-hairpin subdomain and an α-helix subdomain. In general, a C2H2 zinc finger domain consists of about 20-36 amino acids, about 20-30 amino acids, such as 20, 21, 22, 23, 24, 25, 26, 27, 28, 29 or 30 amino acids. The C2H2 zinc finger domain typically comprises an N-terminal β-hairpin and a C-terminal α-helix, wherein the N-terminal β-hairpin comprises two conserved cysteine ​​residues, and the α-helix comprises two conserved histidine residues (see, for example, Fedotova et al., Acta Naturae, 2017 Apr-Jun; 9 (2): 47-58). The motif is also present in the zinc finger domain according to the present invention, including the first and second hybrid zinc finger domains.

[0098] In addition to the first hybrid (non-natural) zinc finger domain, the degradation determinant tag according to the present invention may also include a second (non-natural) hybrid zinc finger domain. In the degradation determinant tag according to the present invention, the second hybrid zinc finger domain is C-terminal relative to the first hybrid zinc finger domain. In such an embodiment, the first hybrid zinc finger domain in the degradation determinant tag according to the present invention is N-terminal relative to the second hybrid zinc finger domain.

[0099] In some embodiments, the first hybrid zinc finger domain and the second hybrid zinc finger domain are directly adjacent to each other, and there is no peptide linker. In some embodiments, the first hybrid zinc finger domain and the second hybrid zinc finger domain are not directly adjacent to each other, but are connected to each other by a short peptide linker. In embodiments where the first hybrid zinc finger domain and the second hybrid zinc finger domain are connected by a linker peptide, such a linker peptide may be composed of, for example, 1, 2, 3, 4, 5, 6, 7 or more amino acids.

[0100] Thus, in some embodiments, the first hybrid zinc finger domain can be linked to the second hybrid zinc finger domain via an additional linker peptide, e.g., the additional linker peptide comprises 1, 2, 3, 4, 5, 6, 7 or more amino acids. However, in some embodiments, there is no additional linker peptide.

[0101] For example, in some embodiments, the linker can be a short stretch of amino acids from a wild-type zinc finger domain, such as from the N-terminal portion or adjacent N-terminal portion of a wild-type zinc finger domain. For example, such an amino acid sequence may be a SGEKP sequence (see Figure 3(derived from the IKZF1 protein in this case - the SGEKP sequence is an endogenous linker between IKZF1 ZF2 and IKZF1 ZF3 in the IKZF1 protein; in the same way, for example, other endogenous linkers may be used as linkers in the context of the present invention, such as comparable endogenous linkers from other C2H2 zinc finger proteins); in some other embodiments, the stretch may be from another wild-type zinc finger domain, and may be, for example, GERP). Experiments have demonstrated that, although such a short stretch may be included, it does not substantially affect the results obtained with the degron tag (and / or the hybrid zinc finger polypeptide according to the present invention), and the skilled person is well able to provide additional linkers suitable in the context of the present invention.

[0102] With respect to the second hybrid zinc finger domain, it has been found that the inclusion of such a second hybrid zinc finger domain can further increase the sensitivity of the degron tag of the invention in controlling protein degradation, protein levels and or cellular activity. Thus, according to this aspect of the invention, a degron tag is provided, wherein the degron tag comprises a first and a second hybrid zinc finger domain as described in detail herein.

[0103] The second hybrid zinc finger domain comprises a third part and a fourth part. The third part and the fourth part are each independently composed of an amino acid sequence. The third part and the fourth part contained in the second hybrid zinc finger domain may be directly adjacent to each other, or may not be directly adjacent to each other. In some embodiments, the third part and the fourth part are connected by a linker peptide, for example, the linker peptide is 1, 2, 3, 4, 5 or more amino acids. Therefore, in some embodiments, the third part and the fourth part may be connected to each other by another linker peptide, for example, the other linker peptide comprises 1, 2, 3, 4, 5, 6, 7 or more amino acids. However, in some embodiments, there is no additional linker peptide between the third part of the second hybrid zinc finger domain and the fourth part of the second hybrid zinc finger domain. In such an embodiment, the third and fourth parts are directly adjacent to each other. Preferably, the third and fourth parts are directly adjacent to each other.

[0104] The third portion of the second hybrid zinc finger domain can be the N-terminal or can be the C-terminal portion from the fourth portion of the second hybrid zinc finger domain. In a preferred embodiment, the third portion is the N-terminal portion of the fourth portion.

[0105] In a preferred embodiment, the third portion consists of 8-30 amino acids, with increasing preference for 11-30, 10-20, 11-20, 10-14, 11-14, 10-11, and most preferably 11 amino acids.

[0106] In a preferred embodiment, the fourth portion consists of 8-30 amino acids, with increasing preference being 12-30, 11-20, 12-20, 11-14, 12-14, and most preferably 12 amino acids.

[0107] In some embodiments, the non-natural second hybrid zinc finger domain is preferably composed of about 16-60 amino acids, preferably about 20-36 amino acids, about 20-30 amino acids, such as 20, 21, 22, 23, 24, 25, 26, 27, 28, 29 or 30 amino acids. In a specific embodiment, the second hybrid zinc finger domain comprises a Cys2 His2 (C2H2) domain, and wherein the hybrid zinc finger domain comprises at least two subdomains (referred to herein as parts), and wherein each subdomain is from a different wild-type zinc finger. For example, wherein the third part of the second hybrid zinc finger domain is from a third wild-type zinc finger, and wherein the fourth part of the second hybrid zinc finger domain is from a different fourth wild-type zinc finger domain. Based on the present disclosure, the skilled person is fully capable of selecting the third part of the second hybrid zinc finger domain from the third wild-type zinc finger and / or is fully capable of selecting the fourth part of the second hybrid zinc finger domain from the fourth wild-type zinc finger. For example, he can appropriately select such a part from wild-type zinc finger domains (in particular wild-type Cys2-His2 (C2H2) zinc finger domains), which are available from various scientific publications and public and well-known gene and protein databases, such as from (Sievers et al. Science. 2018 Nov 2; 362(6414): eaat0572), and which are, for example, known or expected to destabilize proteins (e.g. wild-type proteins comprising such wild-type zinc finger domains) in the presence of IMiDs such as thalidomide, and may control the degradation of such proteins.

[0108] In certain embodiments, the third portion of the second hybrid zinc finger domain comprises the sequence (Z)2C(Z)2C(Z) 5-6 The amino acid sequence represented by , wherein Z represents any amino acid. Thus (Z)2 represents two amino acids, and (Z) 5-6 represents 5 or 6 amino acids. For example, the third portion of the second hybrid zinc finger domain may, for example, comprise the amino acid sequence Z1Z2C3Z4Z5C6Z7Z8Z9Z 10 Z 11 or Z1Z2C3Z4Z5C6Z7Z8Z9Z 10 Z 11 Z 12, wherein each Z (Z1, Z2 . . . etc.) independently represents any amino acid, more specifically, wherein each Z represents any natural or proteinogenic amino acid (e.g., alanine, arginine, asparagine, aspartic acid, cysteine, glutamic acid, glutamine, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine and valine). For example, the skilled person will understand that, for example, Z1 may represent another amino acid other than Z2, for example, or it may represent the same amino acid. The skilled person will understand that C3 represents the presence of cysteine ​​at the third position of the amino acid sequence contained in the third portion of the second hybrid zinc finger domain. Similarly, C6 represents the presence of cysteine ​​at the 6th position. In a preferred embodiment, the third portion of the second hybrid zinc finger domain has the above amino acid sequence (Z)2C(Z)2C(Z) 5-6 , even more preferably (Z)2C(Z)2C(Z)6 and wherein the amino acid sequence is a third Cys2-His2 zinc finger domain (e.g., a wild-type Cys2-His2 zinc finger domain). In certain embodiments, the amino acid sequence of the third portion of the second hybrid zinc finger domain may include an additional short chain of amino acids N-terminal thereto, such as 1-10, preferably 1-5, such as 1, 2, 3, 4 or 5 amino acids of the third or fourth (wild-type) Cys2-His2 zinc finger domain. For example, Figure 3 An example of a degron tag according to the invention is provided (with the positions of amino acid substitutions indicated) in which a short stretch of amino acids SGEKP is present at the N-terminus of the second hybrid zinc finger domain, as described above. Experiments have demonstrated that, although such a short stretch can be included, it does not substantially affect the results obtained with a degron tag (and / or a hybrid zinc finger polypeptide according to the invention).

[0109] As described in detail in the present invention, compared to the first hybrid zinc finger domain contained in the degradation determining subtag according to the present invention, in a preferred embodiment, the second hybrid zinc finger domain is a hybrid zinc finger including a Cys2 His2 (C2H2) zinc finger domain, and wherein the hybrid zinc finger domain comprises at least two subdomains, namely a third part and a fourth part, wherein the amino acid sequence of the third part is derived from a wild-type zinc finger, more specifically a wild-type Cys2 His2 (C2H2) zinc finger.

[0110] In certain embodiments, the fourth portion of the second hybrid zinc finger domain comprises the sequence (Z)6H(Z) 3-4 H represents the amino acid sequence. Therefore, (Z)6 represents 6 amino acids, while (Z) 3-4 represents 3 or 4 amino acids. By way of example, the fourth portion of the second hybrid zinc finger domain may, for example, comprise the amino acid sequence Z 13 Z14 Z 15 Z 16 Z 17 Z 18 H 19 Z 20 Z 21 Z 22 H 23 or Z 13 Z14Z 15 Z 16 Z 17 Z 18 H 19 Z 20 Z 21 Z 22 Z 23 H 24 , where each Z(Z 13 , Z 14 ...etc.) independently represent any amino acid, more specifically, each Z represents any natural or proteinogenic amino acid (e.g., alanine, arginine, asparagine, aspartic acid, cysteine, glutamic acid, glutamine, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine and valine). For example, the skilled person will understand that, for example, Z 13 Can represent, for example, Z 14 Another amino acid other than H, or it may represent the same amino acid. The skilled person understands that H 19 indicates that there is a histidine at position 19 of the amino acid sequence contained in the second portion of the first hybrid zinc finger domain. 23 or H 24 Indicates the presence of histidine cysteine ​​at position 23 or 24 of the sequence (depending on (Z) 3-4 whether it is associated with 3 or 4 amino acids). Note that, for example, Z 13 It does not represent the position relative to the first hybrid zinc finger domain, because, for example, it is explained elsewhere in the present invention that in certain embodiments, there may be a linker between the first hybrid zinc finger domain and the second (hybrid) zinc finger domain. It is also explained herein that the length of the third portion of the second (hybrid) zinc finger may vary, for example, it may be 11 amino acids in length. In a preferred embodiment, the fourth portion of the second hybrid zinc finger domain has the above amino acid sequence (Z)6H(Z) 3-4 H, and wherein the amino acid sequence is of a second Cys2-His2 zinc finger domain, ie, more specifically, of a wild-type Cys2 His2 (C2H2) zinc finger.

[0111] In other words, in a preferred embodiment, the second hybrid zinc finger domain comprised in the degron tag according to the present invention is a hybrid zinc finger domain comprising a Cys2 His2 (C2H2) domain, wherein the hybrid zinc finger domain comprises at least two subdomains, i.e. a third part and a fourth part, and wherein the amino acid sequence of the third part is derived from a wild-type zinc finger, more specifically a wild-type Cys2 His2 (C2H2) zinc finger (i.e. a third Cys2-His2 zinc finger domain), wherein the amino acid sequence of the fourth part is derived from a wild-type zinc finger, more specifically a wild-type Cys2 His2 (C2H2) zinc finger (i.e. a fourth Cys2-His2 zinc finger domain), and wherein, preferably, the third Cys2-His2 zinc finger domain is different from the fourth Cys2-His2 zinc finger domain (e.g., wherein the third Cys2-His2 zinc finger domain is a wild-type zinc finger different from the fourth Cys2-His2 zinc finger domain). Preferably, the amino acid sequence of the third part comprises or is (Z)2C(Z)2C(Z) 5-6 and / or the amino acid sequence of the fourth part comprises or is (Z)6H(Z) 3-4 H.

[0112] In a preferred embodiment the fourth portion is C-terminal relative to the third portion.

[0113] As will be appreciated by those skilled in the art, in addition to the domains, moieties and linkers described above, the degron tag according to the present invention may further comprise amino acids, e.g. from the N-terminus of the first hybrid zinc finger domain or from the C-terminus of the second hybrid zinc finger domain.

[0114] In a preferred embodiment, the degron tag according to the invention is further characterized by the presence of at least two amino acid substitutions in the first hybrid zinc finger domain, wherein the amino acid substitutions in the first part of the first hybrid zinc finger domain are relative to the first part of the first Cys2-His2 zinc finger domain, wherein the amino acid substitutions in the second part of the first hybrid zinc finger domain are relative to the second part of the second Cys2-His2 zinc finger domain, wherein the substitutions are not located at C3, C6, X7, H 19 or H 23 In certain embodiments, X7 is glycine.

[0115] As discussed herein, in embodiments, the first hybrid zinc finger domain comprises a first portion from a first Cys2-His2 zinc finger domain, particularly a first portion from a first wild-type Cys2-His2 zinc finger domain, wherein the first portion comprises the amino acid sequence X1X2C3X4X5C6X7X8X9X 10 X 11(i.e., as present in the first wild-type Cys2-His2 zinc finger domain). As discussed herein, in embodiments, the first hybrid zinc finger domain comprises a second portion from a second Cys2-His2 zinc finger domain, particularly a second portion from a second wild-type Cys2-His2 zinc finger domain, wherein the second portion comprises the amino acid sequence X 12 X 13 X 14 X 15 X 16 X 17 X 18 H 19 X 20 X 21 X 22 H 23 (ie as present in the second wild-type Cys2-His2 zinc finger domain).

[0116] In those embodiments, wherein the degron tag according to the invention is further characterized by the presence of at least two amino acid substitutions in the first hybrid zinc finger domain, wherein the amino acid substitutions are located in the first part of the first hybrid zinc finger domain, the amino acid substitutions being amino acid substitutions relative to the first part of the first Cys2-His2 zinc finger domain from which the sequence was obtained. For example, if X2 is a valine in the first (wild-type) Cys2-His2 zinc finger domain from which the sequence was obtained, and the valine is replaced by, for example, a lysine in a degron tag according to the invention, according to the invention, X2 in the degron tag will be a lysine, and the amino acid substitution is a lysine relative to the valine contained in the wild-type Cys2-His2 zinc finger domain from which it was obtained. In a similar manner, amino acid substitutions in the second part of the first hybrid zinc finger domain are defined herein. For example, if X2 is a valine in the first (wild-type) Cys2-His2 zinc finger domain from which the sequence was obtained, and the valine is replaced by, for example, a lysine in a degron tag according to the invention. 20 is a proline in the second (wild-type) Cys2-His2 zinc finger domain from which the second portion of the sequence is derived, and the proline is replaced by a leucine, for example, in a degron tag according to the invention, wherein X in a degron tag according to the invention is 20 will be leucine, and the amino acid substitution for leucine is relative to the proline contained in the wild-type Cys2-His2 zinc finger domain from which it was derived.

[0117] As previously described, the first hybrid zinc finger domain comprises at least two amino acid substitutions relative to portions of the wild-type first Cys2-His2 zinc finger domain and the second Cys2-His2 zinc finger domain. A skilled person is well able to provide, prepare and identify such amino acid substitutions relative to the wild-type first Cys2-His2 zinc finger domain and the second Cys2-His2 zinc finger domain, for example by comparing the amino acid sequences of the first portion and or the second portion of the first hybrid zinc finger domain.

[0118] In certain embodiments, at least two amino acid substitutions (i.e., substitutions of an amino acid from a wild-type sequence with another different amino acid) are both in the first portion. In certain embodiments, at least two amino acid substitutions are both in the second portion. In some other embodiments, one amino acid substitution is in the first portion and one amino acid substitution is in the second portion. In certain preferred embodiments, the first hybrid zinc finger domain comprises no more than two amino acid substitutions. In certain preferred embodiments, the first hybrid zinc finger domain comprises more than two amino acid substitutions, e.g., 3, 4, 5 or 6 amino acid substitutions, preferably 2, 3 or 4 amino acid substitutions. In certain preferred embodiments, the first zinc finger domain comprises (exactly) two amino acid substitutions, i.e., no more than two amino acid substitutions. In certain preferred embodiments, the first zinc finger domain comprises (exactly) three amino acid substitutions, i.e., no more than three amino acid substitutions. In certain preferred embodiments, the first zinc finger domain comprises (exactly) four amino acid substitutions, i.e., no more than four amino acid substitutions. In those embodiments, wherein the first hybrid zinc finger domain comprises two or more amino acid substitutions, such as three or four amino acid substitutions, in preferred embodiments, for example, the third and / or fourth amino acid substitutions are selected or selected from the substitutions disclosed herein, such as those listed in Table 1. In those embodiments, wherein the first hybrid zinc finger domain comprises, for example, four amino acid substitutions (or six), in preferred embodiments, four amino acid substitutions (or six) are selected from the substitution pairs disclosed herein, such as those listed in Table 2 (e.g., Q12R K13V G14N K21A) and / or as the positions and amino acid pairs to be substituted listed in Table 4. As discussed herein, in preferred embodiments, wherein the first hybrid zinc finger domain comprises 4 amino acid substitutions, the first hybrid zinc finger domain according to the present invention comprises the amino acid sequence according to SEQ ID NO: 135 (LQCEICGFTCRRVNNLLRHIALH; i.e., the quadruple substitution Q12R / K13V / G14N / K21A) and / or the degron tag according to the present invention comprises the amino acid sequence according to SEQ ID NO: 136 (LQCEICGFTCRRVNNLLRHIALHSGEKPFKCHLCNYACRRKDSVVAHK AKSH).

[0119] In a preferred embodiment, the substitution is not at C3, C6, X7, H 19 , or H 23 In certain embodiments, X7 is G7.

[0120] Surprisingly, it was found that by introducing at least two amino acid substitutions in the first part and / or the second part of the first hybrid zinc finger domain, the amino acid substitutions relative to the first part of the (wild-type) first Cys2-His2 zinc finger domain and the second part of the (wild-type) second Cys2-His2 zinc finger domain, a degrader tag can be provided with a highly enhanced or increased sensitivity to IMiD molecules, such as thalidomide or an analog, relative to the wild-type zinc finger domain and a hybrid zinc finger domain comprising a wild-type subdomain (as described herein) and not comprising at least two amino acid substitutions. Interestingly, although it was found that the introduction of one amino acid substitution may also enhance or increase sensitivity to ImiD molecules, unexpectedly, the introduction of further amino acid substitutions may even further enhance or increase sensitivity to ImiD molecules, as shown in the examples and description of the present invention.

[0121] Therefore, according to this aspect of the invention, a degradation determinant tag is provided, which comprises at least a first hybrid zinc finger domain, wherein the first hybrid zinc finger domain comprises at least two amino acid substitutions relative to a wild-type zinc finger domain (or a portion thereof), the hybrid zinc finger domain is composed of the wild-type zinc finger domain (or a portion thereof), and the degradation determinant tag has enhanced or increased sensitivity to ImiD molecules.

[0122] In certain embodiments, at least two amino acid substitutions are located directly adjacent to each other, and in other embodiments, the positions of the amino acid substitutions are separated from each other by at least 1, 2, 3, 4, 5, 6, 7, 8, 10, 11, 12, 13 or more amino acids (i.e., the unsubstituted amino acids), for example, as shown in the accompanying tables, graphs and examples.

[0123] Although any amino acid substitution is allowed in principle, it is preferred that the amino acid substitution at a specific position in the first hybrid zinc finger domain is as described herein (either with respect to the substituted amino acid or with respect to the substituting amino acid). The skilled person can provide amino acid substitutions and degradation determinant tags according to the present invention without undue effort based on the information disclosed herein.

[0124] Without intending to be bound by theory, the inventors believe that the observed enhanced or increased sensitivity of the degron tag and / or the hybrid zinc finger polypeptide according to the invention to ImiD molecules is at least partly due to a change or improvement in the interaction of the degron tag, cereblon and the immunomodulatory drug (ImiD). Therefore, in a preferred embodiment, a degron tag according to the invention and / or a hybrid zinc finger polypeptide according to the invention is provided, wherein the degron tag and / or the hybrid zinc finger polypeptide is capable of binding to a complex formed between cereblon (CRBN) and an immunomodulatory drug (IMiD).

[0125] The present invention also provides a degradation determinant tag and / or a hybrid zinc finger polypeptide according to the present invention, wherein the first part is a β-hairpin loop of a first Cys2-His2 zinc finger domain, the second part is an α-helical region of a second Cys2-His2 zinc finger domain, the third part is a β-hairpin loop of a third Cys2-His2 zinc finger domain, and / or the fourth part is an α-helical region of a fourth Cys2-His2 zinc finger domain. As mentioned above, "a first, second, third or fourth Cys2-His2 zinc finger domain" refers to a Cys2-His2 zinc finger domain found in nature, i.e., a Cys2-His2 zinc finger domain from a wild-type zinc finger protein. As described above, in the degradation determinant tag and / or hybrid zinc finger polypeptide according to the invention, the first hybrid zinc finger domain may comprise at least two amino acid substitutions. As described above, portions of these wild-type Cys2-His2 zinc finger domains are used to provide a degron tag and / or a hybrid zinc finger polypeptide according to the present invention. According to a preferred embodiment of the present invention, the first portion used is the β-hairpin loop of the first Cys2-His2 zinc finger domain, the second portion used is the α-helical region of the second Cys2-His2 zinc finger domain, the third portion used is the β-hairpin loop of the third Cys2-His2 zinc finger domain, and / or the fourth portion used is the α-helical region of the fourth Cys2-His2 zinc finger domain. The zinc finger domain includes a β-hairpin loop and an α-helical region, and the skilled person knows how to provide a β-hairpin loop portion and / or an α-helical region portion of a (wild-type) Cys2-His2 zinc finger domain. Representative examples are well known to those skilled in the art and include those disclosed and described herein. Examples of zinc fingers containing a β-hairpin loop and an α-helical region include, but are not limited to, (human) IKZF1, IKZF2, IKZF3, SALL4, ZFP91, GZF1, ZNF653, ZNF692, ZNF827, ZBTB39, WIZ, ZNF98, ZNF654, ZNF787, ZNF 276, ZNF582, ZNF517 and E4F1 (see also Uniprot Accession Nos.: Q13422, Q9UKS7, Q9UKT9, Q9UJQ4, Q96JP5, Q9H116, Q96CK0, Q9BU19, Q17R98, O15060, O95785, A6NK75, Q8IZM8, Q6DD87, Q8N554, Q96NG8, Q6ZMY9, Q66K89).As disclosed above, assuming that the degron tag and / or hybrid zinc finger polypeptide according to the present invention is a substrate for the CRBN-IMiD complex, and / or exhibits an enhanced or increased sensitivity to the IMiD molecule (relative to, for example, the wild-type situation), the degron tag and / or hybrid zinc finger polypeptide according to the present invention may include one or more amino acid residues relative to the N-terminus of the β-hairpin portion, may include one or more amino acid residues between the β-hairpin portion and the α-helical portion, and one or more amino acid residues relative to the C-terminus of the α-helical portion. Assuming that the degron tag maintains a zinc finger-like fold and exhibits properties as disclosed herein, these additional amino acids may correspond to or differ from residues in the native Cys2-His2 zinc finger domain.

[0126] In an embodiment of the invention, a degron tag and / or hybrid zinc finger polypeptide according to the invention is provided, wherein the first substitution is in the second part and the second substitution is in the first part or the second part. Although at least two amino acid substitutions may be included in the first part at the same time, or both may be included in the second part at the same time, or one may be included in the first part and the second may be included in the second part, in a preferred embodiment, at least one amino acid substitution is present in the second part. It was found that particularly suitable degron tags and / or hybrid zinc finger polypeptides according to the invention can be provided, wherein at least one amino acid substitution is located in the second part, i.e., in the alpha helical part of the first hybrid zinc finger domain. The second amino acid substitution may be present in the second part, or it may be present in the first part (i.e., in the beta hairpin loop).

[0127] Also provided is a degron tag and / or a hybrid zinc finger polypeptide according to the present invention, wherein at least one substituted position is selected from the group consisting of X1, X4, X 12 , X 13 , X 14 , X 15 , X 17 , X 21 and X 22 In particular, it was found that the amino acid substitution at one of these positions in the first hybrid zinc finger domain allows providing a degron tag and / or hybrid zinc finger polypeptide according to the invention with an increased or enhanced sensitivity to IMiD molecules. Without being bound by theory, as shown in the examples, it is believed that especially these positions are important positions in the first hybrid zinc finger domain that allow the improved or increased sensitivity to IMiDs that can be observed. Preferably, the substitution amino acid is as disclosed herein.

[0128] In a preferred embodiment, a degron tag and / or a hybrid zinc finger polypeptide according to the invention is provided, and wherein at least one substitution present in the degron tag and / or the hybrid zinc finger polypeptide according to the invention (or present in the first hybrid zinc finger domain) is selected from those listed in Table 1. Table 1 lists different positions X1-X 22 , wherein in a preferred embodiment, there may be a substitution in a degron tag and / or a hybrid zinc finger polypeptide according to the invention and a substitution amino acid (i.e., an amino acid contained in that position in a degron tag and / or a hybrid zinc finger polypeptide according to the invention; a one-letter code). Preferably, both amino acid substitutions (both positions and amino acid substitutions) are selected from those listed in Table 1. The skilled person will understand that when two amino acid substitutions are selected from Table 1 (or any other list provided herein), each amino acid substitution is at a different position. At the same time, the skilled person will understand that a substitution amino acid is meant to represent an amino acid that is different from a natural amino acid (i.e., different from that present in a wild-type Cys2-His2 zinc finger domain for the first part or the second part of the first hybrid zinc finger domain). In this regard, it should be noted that the present invention is not particularly limited to a specific wild-type Cys2-His2 zinc finger domain used to provide the first part, the second part (and / or the third and fourth parts as discussed herein).

[0129] Likewise, the present invention also encompasses the use of positions and substitutions as listed in Table 1 (or any other list provided herein): can be used to provide any suitable first or second portion of a (wild-type) Cys2-His2 zinc finger domain of a first hybrid zinc finger domain according to the present invention. In other words, as long as the degron tag and / or hybrid zinc finger polypeptide according to the present invention maintains a zinc finger-like fold and exhibits properties as disclosed herein (e.g., sensitivity to IMiDs in the context of protein degradation), the positions and substitution amino acids listed in Table 1 (or any other list provided herein) are applicable to any suitable first hybrid zinc finger domain.

[0130] However, in a preferred embodiment, the positions and substitutions are relative to the first hybrid zinc finger domain used in the examples of the present invention, i.e., wherein the first portion of the first hybrid zinc finger domain is the β-hairpin region of ZFP91 ZF4, and the second portion of the first hybrid zinc finger domain is the α-helical region of IKZF1 ZF2 (see Figure 3 ; wherein the first hybrid zinc finger domain of the "parent degradation determinant tag" used in the example is represented by a diagram).

[0131] Table 1 - Preferred positions and substitutions (substituted amino acids)

[0132]

[0133]

[0134] In a preferred embodiment, a degron tag and / or a hybrid zinc finger polypeptide according to the invention is provided, and wherein the at least two substitutions are selected from those listed in Table 2. Table 2 lists preferred combinations of two amino acid substitutions at two different positions in the first hybrid zinc finger domain according to the invention as described herein (each row shows a preferred combination of two positions in the first hybrid zinc finger domain and the corresponding substituted amino acids; for example 4R and 12L indicate that in this combination, the amino acid at position 4 in the first hybrid zinc finger domain is substituted by arginine (R), and the amino acid at position 12 in the first hybrid zinc finger domain is substituted by leucine (L) - in other words the original amino acid in the portion obtained from the wild-type Cys2-His2 zinc finger domain, position 4 is substituted by arginine and position 12 is substituted by leucine). In a preferred embodiment of the invention, the at least two substitutions are selected from any combination shown in Table 2.

[0135] Table 2 - Preferred positions and combinations of substitutions (substituted amino acids)

[0136]

[0137]

[0138] The skilled artisan will understand that a replacement amino acid is meant to represent an amino acid that is different from the natural amino acid (i.e., different from that present in the wild-type Cys2-His2 zinc finger domain used for the first part or the second part of the first hybrid zinc finger domain). In this regard, it should be noted that the present invention is not particularly limited to a specific wild-type Cys2-His2 zinc finger domain used to provide the first part, the second part (and / or the third and fourth parts as discussed herein).

[0139] Likewise, the present invention also encompasses the use of positions and substitutions as listed in Table 2 (or any other list provided herein) - can be used to provide any suitable first or second portion of a (wild-type) Cys2-His2 zinc finger domain of a first hybrid zinc finger domain according to the present invention. In other words, as long as the degron tag and / or hybrid zinc finger polypeptide according to the present invention maintains a zinc finger-like fold and exhibits properties as disclosed herein (e.g., sensitivity to IMiDs in the context of protein degradation), the positions and substitution amino acids listed in Table 2 (or any other list provided herein) are applicable to any suitable first hybrid zinc finger domain.

[0140] However, in a preferred embodiment, the positions and substitutions are relative to the first hybrid zinc finger domain used in the examples of the present invention, i.e., wherein the first portion of the first hybrid zinc finger domain is the β-hairpin region of ZFP91 ZF4, and the second portion of the first hybrid zinc finger domain is the α-helical region of IKZF1 ZF2 (see Figure 3 ; wherein the first hybrid zinc finger domain of the "parent degradation determinant tag" used in the example is represented by a diagram).

[0141] In addition, the major amino acid substitutions Q12R, Q12K, N15R and L22R frequently observed in the examples, when combined with the minor amino acid substitutions listed in Table 8 (see below) (i.e., EI Q12R / K13V=0.006877267, where EI Q12R=0.167217557), further improved the sensitivity to IMiDs in a synergistic manner (i.e., EI Q12R / K13V=0.006877267, and EI Q12R=0.167217557). Therefore, in particular, in a preferred embodiment of the present invention, a combination of the amino acid substitutions mentioned in Table 8 is used / provided, such as 12R and 13T or 22R and 14L, etc.

[0142] In a preferred embodiment, a degron tag and / or a hybrid zinc finger polypeptide according to the invention is provided, wherein the amino acid in the substituted first part and / or the amino acid in the substituted second part is selected from those listed in Table 3.

[0143] Table 3 lists preferred amino acids substituted in the first hybrid zinc finger domain of the degron tag and / or hybrid zinc finger polypeptide according to the present invention. In other words, in a preferred embodiment of the present invention, the positions and / or positions and substituted amino acids are selected from those listed in Table 3. Thus, according to a preferred embodiment of the present invention, at least two amino acid substitutions are selected from the combination of positions 1, 4, 5, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 20, 21 and 22, and wherein the substituted amino acids are a combination of two amino acids as listed in Table 3.

[0144] Table 3 - Preferred positions and substituted amino acids

[0145] L1 E4 I5 F8 T9 C10 R11 Q12 K13 G14 N15 L16 L17 R18 I20 K21 L22

[0146] Preferably, both substituted amino acids (both position and amino acid substitution) are selected from those listed in Table 3. The skilled person will appreciate that the preferred amino acids, for example as shown in Table 3, may be replaced by any suitable amino acids, as long as it provides a degron tag and / or a hybrid zinc finger polypeptide according to the invention. However, in a preferred embodiment, the preferred amino acid combinations of amino acids listed in Table 3 are replaced by the corresponding amino acids listed in Table 1 or the corresponding amino acid combinations shown in Table 2 (wherein corresponding refers to, for example, the corresponding positions in the first hybrid zinc finger domain disclosed herein).

[0147] The skilled person will understand that when both substituted amino acids are selected from those listed in Table 3 (or any other list provided herein), each amino acid substitution is at a different position. At the same time, the skilled person will understand that a substituted amino acid is meant to indicate that the amino acid substituted by another amino acid is different from the natural amino acid (i.e., different from the wild-type Cys2-His2 zinc finger domain present in the first part or the second part of the first hybrid zinc finger domain). In this regard, it should be noted that the present invention is not particularly limited to a specific wild-type Cys2-His2 zinc finger domain used to provide the first part, the second part (and / or the third and fourth parts as discussed herein).

[0148] Likewise, the present invention also encompasses the use of positions and substitutions as listed in Table 3 (or any other list provided herein) - can be used to provide any suitable (wild-type) first or second portion of a Cys2-His2 zinc finger domain of a first hybrid zinc finger domain according to the present invention. In other words, as long as the degron tag and / or hybrid zinc finger polypeptide according to the present invention maintains a zinc finger-like fold and exhibits properties as disclosed herein (e.g., sensitivity to IMiDs in the context of protein degradation), the positions and substituted amino acids listed in Table 3 (or any other list provided herein) are applicable to any suitable first hybrid zinc finger domain.

[0149] However, in a preferred embodiment, the positions and substitutions are relative to the first hybrid zinc finger domain used in the examples of the present invention, i.e., wherein the first portion of the first hybrid zinc finger domain is the β-hairpin region of ZFP91 ZF4, and the second portion of the first hybrid zinc finger domain is the α-helical region of IKZF1 ZF2 (see Figure 3 ; wherein the first hybrid zinc finger domain of the "parent degradation determinant tag" used in the example is represented by a diagram).

[0150] In a preferred embodiment, a degron tag and / or a hybrid zinc finger polypeptide according to the invention is provided, wherein at least two substituted amino acids in the first part and / or the second part are selected from those listed in Table 4.

[0151] Table 4 lists preferred combinations of two amino acids substituted at two different positions in the first hybrid zinc finger domain according to the present invention as described herein (each row shows a preferred combination of two positions in the first hybrid zinc finger domain and the corresponding substituted amino acids; for example E4 and Q12 indicate that in this combination, the amino acid at position 4 of the first hybrid zinc finger domain is substituted by glutamic acid (E), and the substituted amino acid at position 12 is substituted by glutamine (Q) - in other words, the original amino acids of the portion obtained from the wild-type Cys2-His2 zinc finger domain, position 4 is substituted by glutamic acid and position 12 is substituted by glutamine). In a preferred embodiment of the present invention, at least two substituted amino acids are selected from any combination shown in Table 4. The skilled person will appreciate that amino acids, such as the preferred amino acids shown in Table 4, may be substituted by any suitable amino acids, as long as it provides a degron tag and / or a hybrid zinc finger polypeptide according to the present invention. However, in a preferred embodiment, amino acids, preferably the amino acid combinations listed in Table 4, are replaced by the corresponding amino acids listed in Table 1 or the corresponding amino acid combinations shown in Table 2 (wherein corresponding refers to, for example, the corresponding positions in the first hybrid zinc finger domain disclosed herein).

[0152] Table 4 - Preferred positions and combinations of substituted amino acids

[0153]

[0154]

[0155]

[0156] The skilled artisan will understand that a replacement amino acid is meant to represent an amino acid that is different from the natural amino acid that is replaced (i.e., different from that present in the wild-type Cys2-His2 zinc finger domain used for the first part or the second part of the first hybrid zinc finger domain). In this regard, it should be noted that the present invention is not particularly limited to a specific wild-type Cys2-His2 zinc finger domain used to provide the first part, the second part (and / or the third and fourth parts as discussed herein).

[0157] Likewise, the present invention also encompasses the use of positions and substitutions as listed in Table 4 (or any other list provided herein): can be used to provide any suitable (wild-type) first or second portion of a Cys2-His2 zinc finger domain of a first hybrid zinc finger domain according to the present invention. In other words, as long as the degron tag and / or hybrid zinc finger polypeptide according to the present invention maintains a zinc finger-like fold and exhibits properties as disclosed herein (e.g., sensitivity to IMiDs in the context of protein degradation), the positions listed in Table 4 and the substituted amino acids (or any other list provided herein) are applicable to any suitable first hybrid zinc finger domain.

[0158] However, in a preferred embodiment, the positions and substituted amino acids are relative to the first hybrid zinc finger domain used in the examples of the present invention, i.e., wherein the first part of the first hybrid zinc finger domain is the β-hairpin region of ZFP91 ZF4, and the second part of the first hybrid zinc finger domain is the α-helical region of IKZF1 ZF2 (see Figure 3 ; wherein the first hybrid zinc finger domain of the "parent degradation determinant tag" used in the example is represented by a diagram).

[0159] In yet another embodiment, a degron tag and / or a hybrid zinc finger polypeptide according to the invention is provided, and wherein

[0160] (1) the first Cys2-His2 zinc finger domain is selected from the group consisting of IKZF1 ZF2, IKZF3 ZF2, ZFP91 ZF4, ZNF654 ZF1, ZNF787 ZF5, ZNF653 ZF4, ZNF276 ZF4, ZNF692 ZF4, ZNF582 ZF9, ZNF517 ZF10, E4F1 ZF2, and ZNF827 ZF1, preferably ZFP91 ZF4;

[0161] (2) the second Cys2-His2 zinc finger domain is selected from the group consisting of IKZF1 ZF2, IKZF3 ZF2, ZFP91 ZF4, ZNF654 ZF1, ZNF787 ZF5, ZNF653 ZF4, ZNF276 ZF4, ZNF692 ZF4, ZNF582 ZF9, ZNF517 ZF10, E4F1 ZF2, and ZNF827 ZF1, preferably IKZF1 ZF2;

[0162] (3) the third Cys2-His2 zinc finger domain is selected from the group consisting of IKZF1 ZF3, IKZF3 ZF3, ZFP91 ZF5, ZNF653 ZF5, ZNF276 ZF5, ZNF827 ZF2, and ZNF692 ZF5, preferably IKZF1 ZF3; and / or

[0163] (4) The fourth Cys2-His2 zinc finger domain is selected from the group consisting of IKZF1 ZF3, IKZF3 ZF3, ZFP91 ZF5, ZNF653 ZF5, ZNF276 ZF5, ZNF827 ZF2, and ZNF692 ZF5, preferably ZFP91 ZF5.

[0164] The present invention is not particularly limited to a specific (wild-type) Cys2-His2 zinc finger domain, which provides a first hybrid zinc finger domain and a second hybrid zinc finger domain, particularly a first, second, third and / or fourth part in the second hybrid zinc finger domain, respectively. In the art, different wild-type or naturally occurring Cys2-His2 zinc finger domains have been described, and the zinc finger domains are suitable for use in degradation determinant systems including the use of IMiDs (see, for example, by (Sievers et al. Science. 2018 Nov 2; 362(6414): eaat0572)). The skilled person will appreciate that such a Cys2-His2 zinc finger domain, which includes a typical β hairpin loop and an α helix, can therefore be suitably used in the present invention and provide, for example, a first hybrid zinc finger domain and a second hybrid zinc finger domain (particularly a second hybrid zinc finger domain), respectively. The first, second, third and / or fourth part. And wherein, in the first and / or second part, at least two amino acids may be replaced and are described in detail herein. Thus, a skilled person can easily provide such a degron tag and / or a hybrid zinc finger polypeptide according to the present invention, which retains the zinc finger-like fold (β-hairpin loop and α helix) and exhibits the properties as disclosed herein (e.g., sensitivity to IMiD in the context of protein degradation)

[0165] However, in a preferred embodiment

[0166] (1) the first Cys2-His2 zinc finger domain is selected from the group consisting of IKZF1 ZF2, IKZF3 ZF2, ZFP91 ZF4, ZNF654 ZF1, ZNF787 ZF5, ZNF653 ZF4, ZNF276 ZF4, ZNF692 ZF4, ZNF582 ZF9, ZNF517 ZF10, E4F1 ZF2 and ZNF827 ZF1, preferably ZFP91 ZF4;

[0167] (2) the second Cys2-His2 zinc finger domain is selected from the group consisting of IKZF1 ZF2, IKZF3 ZF2, ZFP91 ZF4, ZNF654 ZF1, ZNF787 ZF5, ZNF653 ZF4, ZNF276 ZF4, ZNF692 ZF4, ZNF582 ZF9, ZNF517 ZF10, E4F1 ZF2, and ZNF827 ZF1, preferably IKZF1 ZF2;

[0168] (3) the third Cys2-His2 zinc finger domain is selected from the group consisting of IKZF1 ZF3, IKZF3 ZF3, ZFP91 ZF5, ZNF653 ZF5, ZNF276 ZF5, ZNF827 ZF2, and ZNF692 ZF5, preferably IKZF1 ZF3; and / or

[0169] (4) the fourth Cys2-His2 zinc finger domain is selected from the group consisting of IKZF1 ZF3, IKZF3 ZF3, ZFP91 ZF5, ZNF653 ZF5, ZNF276 ZF5, ZNF827 ZF2, and ZNF692 ZF5, preferably ZFP91 ZF5;

[0170] In other words, in some embodiments, the amino acid sequence of the Cys2-His2 zinc finger domain used to select the first part and / or the second part (see below) is selected from the group consisting of: SEQ ID NO: 116 (IKZF1 ZF2-FQCNQCGASFTQKGNLLRHIKLH), SEQ ID NO: 117 (IKZF3 ZF2-FQCNQCGASFTQKGNLLRHIKLH), SEQ ID NO: 118 (ZFP91 ZF4-LQCEICGFTCRQKASLNWHMKKH), SEQ ID NO: 119 (ZNF654 ZF1-FACVICGRKFRNRGLMQKHLKNH), SEQ ID NO: 120 (ZNF787 ZF5-FVCPRCGRGFSQPKSLARHLRLH), SEQ ID NO: 121 (ZNF653 ZF4-LQCEICGYQCRQRASLNWHMKKH), SEQ ID NO: 122 (ZNF787 ZF5-FVCPRCGRGFSQPKSLARHLRLH), SEQ ID NO: 123 (ZNF653 ZF4-LQCEICGYQCRQRASLNWHMKKH), SEQ ID NO: 124 (ZNF787 ZF5-FVCPRCGRGFSQPKSLARHLRLH), SEQ ID NO: 125 NO:122(ZNF276 ZF4–LQCEVCGFQCRQRASLKYHMTKH), SEQ ID NO:123(ZNF692 ZF4–LQCEICGFTCRQKASLNWHQRKH), SEQ ID NO:124(ZNF582 ZF9–YQCKVCGRAFKRVSHLTVHYRIH), SEQ ID NO:125(ZNF517 ZF10–YRCRACGRACSRLSTLIQHQKVH), SEQ ID NO:126 (E4F1 ZF2–HECKLCGASFRTKGSLIRHHRRH), and / or SEQ ID NO:127 (ZNF827 ZF1–FQCPICGLVIKRKSYWKRHMVIH).

[0171] In other words, in some embodiments, the amino acid sequence of the Cys2-His2 zinc finger domain used to select the third part and / or the fourth part (see below) is selected from the group consisting of: SEQ ID NO: 128 (IKZF1 ZF3-FKCHLCNYACRRRDALTGHLRTH), SEQ ID NO: 129 (IKZF3 ZF3-FKCHLCNYACQRRDALTGHLRTH), SEQ ID NO: 130 (ZFP91 ZF5-FSCNICGKKFEKKDSVVAHKAKSH), SEQ ID NO: 131 (ZNF653 ZF5-FTCDRCGKRFEKLDSVKFHTLKSH), SEQ ID NO: 132 (ZNF276 ZF5-FACDQCGRRFEKAHNLNVHMSMVH), SEQ ID NO: 133 (ZNF827 ZF2-HQCPLCPFRCARKDNLKSHMKVH) and / or SEQ ID NO: NO: 134 (ZNF692ZF5–FPCEFCGKRFEKPDSVAAHRSKSH).

[0172] According to this embodiment, the first Cys2-His2 zinc finger domain provides a first portion of the first hybrid zinc finger domain and is selected from those listed above.

[0173] According to this embodiment, the second Cys2-His2 zinc finger domain provides the second portion of the second hybrid zinc finger domain and is selected from those listed above.

[0174] In the degron tag and / or hybrid zinc finger polypeptide according to the invention, these first and second parts provide a first hybrid zinc finger domain and further comprise at least two amino acid substitutions relative to the first and / or second part provided by the first and second Cys2-His2 zinc finger domains.

[0175] According to this embodiment, the third Cys2-His2 zinc finger domain provides the third portion of the second hybrid zinc finger domain and is selected from those listed above.

[0176] According to this embodiment, the fourth Cys2-His2 zinc finger domain provides the fourth part of the second hybrid zinc finger domain and is selected from those listed above. As discussed herein, the second zinc finger in the degron tag and / or hybrid zinc finger polypeptide according to the present invention can be a hybrid zinc finger domain in certain embodiments, or it can be a non-hybrid zinc finger domain. In the latter case, the second zinc finger can therefore also be selected from any one of the third or fourth Cys2-His2 zinc finger domains described above (providing both the first part and the second part from the same Cys2-His2 zinc finger domain).

[0177] In a preferred embodiment, at least one, two, three or four of the first, second, third and fourth zinc finger domains listed above are selected. In a preferred embodiment, all of the first, second, third and fourth Cys2-His2 zinc finger domains listed above are selected. In a preferred embodiment, at least the first and second Cys2-His2 zinc finger domains are selected from those listed above. In a preferred embodiment, at least the third and fourth Cys2-His2 zinc finger domains are selected from those listed above.

[0178] In a highly preferred embodiment, the beta hairpin loop (or first part) of the first hybrid zinc finger domain is from ZFP91 ZF4, and the alpha helix (or second part) of the first hybrid zinc finger is from IKZF1 ZF2. In another highly preferred embodiment, the beta hairpin loop (or third part) of the second hybrid zinc finger domain is from IKZF1 ZF3, and the alpha helix (or fourth part) of the second hybrid zinc finger is from ZFP91 ZF5.

[0179] In certain embodiments, one of the first and second Cys2-His2 zinc finger domains and one of the third and fourth Cys2-His2 zinc finger domains are from the same zinc finger protein (eg, a ZF4 domain from ZFP91 and a ZF5 domain from ZFP91). In certain embodiments, the first and second Cys2-His2 zinc finger domains are from two different zinc finger proteins, the third and fourth Cys2-His2 zinc finger domains are from the same two different zinc finger proteins (e.g., the first Cys2-His2 zinc finger domain and the fourth Cys2-His2 zinc finger domain are both from ZFP91 (zinc finger domains ZF4 and ZF5, respectively), and the second Cys2-His2 zinc finger domain and the third Cys2-His2 zinc finger domain are both from different zinc finger proteins, such as IKZF1 (zinc finger domains ZF2 and ZF3, respectively). When two different Cys2-His2 zinc finger domains from the same zinc finger protein are provided, the Cys2-His2 zinc finger domain that is N-terminally oriented relative to the other in the wild-type zinc finger protein is also preferably N-terminally oriented relative to the other in the degradation-determining self-tag and / or hybrid zinc finger polypeptide according to the present invention.

[0180] The sequences and structures of the listed Cys2-His2 zinc finger domains are well known to the skilled person and can be obtained from various scientific publications and databases.

[0181] As already briefly discussed, in embodiments of the present invention, there are also provided degron tags and / or hybrid zinc finger polypeptides according to the present invention, wherein at least two amino acid substitutions are introduced in a first hybrid zinc finger domain, the first part of which has an amino acid sequence according to SEQ ID NO: 101 (LQCEICGFTCR-ZFP91 ZF4 (first part)), and / or the second part of which has an amino acid sequence according to SEQ ID NO: 102 (QKGNLLRHIKLH-IKZF1 ZF2 (second part)), and / or a first hybrid zinc finger domain having an amino acid sequence according to SEQ ID NO: 103 (LQCEICGFTCRQKGNLLRHIKLH-(ZFP91 ZF4 / IKZF1 ZF2 first hybrid zinc finger domain)). In preferred embodiments, at least two amino acid substitutions according to the present invention may be introduced in these sequences.

[0182] In a further preferred embodiment, a degron tag and / or a hybrid zinc finger polypeptide according to the invention is provided, wherein at least two amino acid substitutions are introduced (e.g. having a sequence according to any one of SEQ ID NOs: 101-103), and wherein its third part has the amino acid sequence according to SEQ ID NO: 104 (FKCHLCNYACRR-(IKZF1 ZF3 (third part)) and / or its fourth part has the amino acid sequence according to SEQ ID NO: 105 (KDSVVAHKAKSH (ZFP91 ZF5 (fourth part)) and / or a second hybrid zinc finger domain having the amino acid sequence according to SEQ ID NO: 106 (FKCHLCNYACRRKDSVVAHKAKSH-second hybrid zinc finger domain).

[0183] In a further preferred embodiment, a degron tag and / or a hybrid zinc finger polypeptide according to the invention is provided, wherein at least two amino acid substitutions are introduced, and wherein the degron tag and / or the hybrid zinc finger polypeptide has an amino acid sequence according to SEQ ID NO: 107 (LQCEICGFTCRQKGNLLRHIKLHSGEKPFKCHLCNYACRRKDSVVAHK AKSH). In a preferred embodiment, at least two amino acid substitutions according to the invention may be introduced into these sequences.

[0184] In a preferred embodiment, a degradation determinant tag and / or a hybrid zinc finger polypeptide according to the present invention is provided, and the first hybrid zinc finger domain comprising two substitutions therein is selected from those listed in Table 5. Table 5 lists the preferred first hybrid zinc finger domain (or hybrid zinc finger polypeptide) according to the present invention. SEQ ID NO: 135 is also a preferred first hybrid zinc finger domain (or hybrid zinc finger polypeptide) according to the present invention. SEQ ID NO: 136 is included in the preferred degradation determinant tag according to the present invention. These preferred zinc finger domains are those that show the most beneficial EI index (enrichment index) calculated according to the Examples section. The results are summarized in Table 6.

[0185] Table 5 - Preferred first hybrid zinc finger domains

[0186]

[0187]

[0188] Table 6 - EI index (enrichment index) of the first hybrid zinc finger domain listed in Table 5

[0189]

[0190]

[0191]

[0192] Indeed, it was surprisingly found that having at least two substitutions in the first hybrid zinc finger domain as described herein provides a degron tag and / or hybrid zinc finger polypeptide according to the invention which has an enhanced or increased sensitivity towards IMiDs, in particular compared to, for example, those comprising only one substitution in the first hybrid zinc finger domain. For example, when the first hybrid zinc finger domain used in the examples contained only one mutation (substitution L1Y, providing the sequence YQCEICGFTCRQKGNLLRHIKLH (SEQ ID NO: 108), the corresponding EI value was at least 10-15 times higher (= indicating a degron tag and / or hybrid zinc finger polypeptide that is less sensitive to IMiDs) than the EI value determined for SEQ ID. NO 36 (and at least 5 times compared to SEQ ID. NO 100). This therefore shows that, despite the introduction of a second or further substitution, such as a third or fourth amino acid substitution, into the first hybrid zinc finger domain, the sensitivity of the resulting first hybrid zinc finger domain (with at least two substitutions) is surprisingly significantly improved. Exemplary EI values ​​obtained for the first hybrid zinc finger domain with different single mutations used in the examples herein are shown in Table 7.

[0193] Table 7 - EI index (enrichment index) of single mutations of selected first hybrid single domains

[0194] Location mutation EI Index L1 H 0.636477685 L1 W 0.637400065 Q2 D 0.917930978 Q2 T 0.946831062 E4 A 0.365806836 E4 W 0.392513782 I5 V 0.418917893 F8 Y 0.452021407 T9 K 0.424730805 T9 R 0.533275349 C10 S 0.35751446 R11 K 0.608245997 R11 G 0.645443413 Q12 F 0.307819119 Q12 Y 0.34576953 K13 Q 0.278922437 K13 P 0.280186349 G14 K 0.306447148 N15 K 0.205033159 N15 T 0.298069121 L16 F 0.516568047 L16 M 0.552891676 L17 Y 0.35840278 L17 Q 0.457417453 R18 K 0.285725983 R18 F 0.361286698 20I Y 0.3727609 20I R 0.453876376 K21 S 0.294182544 K21 Q 0.300387833 L22 R 0.372469467 L22 S 0.401515932

[0195] Although in preferred embodiments, the degron tag and / or hybrid zinc finger polypeptide according to the present invention comprises a first hybrid zinc finger domain comprising any of the sequences listed in Table 5, it is also envisioned that the first hybrid zinc finger domain of the degron tag and / or hybrid zinc finger polypeptide according to the present invention comprises a β-hairpin of the first hybrid zinc finger domain listed in Table 5 or an α-helix of the first hybrid zinc finger domain listed in Table 5, and further comprises different α-helical and β-hairpin portions, respectively. For example, in preferred embodiments, it is envisioned that the first hybrid zinc finger domain comprises a combination of a β-hairpin portion of any of the sequences listed in Table 5 and an α-helical portion of any of the sequences listed in Table 5. In certain embodiments, the first hybrid zinc finger domain comprises a combination of a β-hairpin portion of any of the sequences listed in Table 5 and another α-helical portion that is not necessarily listed in Table 5. In certain embodiments, the first hybrid zinc finger domain comprises a combination of a β-hairpin portion that is not necessarily listed in Table 5 and an α-helical portion of any of the sequences listed in Table 5.

[0196] In certain embodiments, the first hybrid zinc finger domain of the degron tag and / or zinc finger polypeptide according to the invention is any one of those listed in Table 5, preferably any one of SEQ ID 1-90, SEQ ID 1-80, SEQ ID 1-70, SEQ ID 1-60, SEQ ID 1-50, SEQ ID 1-40, SEQ ID 1-30, SEQ ID 1-20, SEQ ID 1-10, or SEQ ID NO: 135. In another embodiment, the first hybrid zinc finger domain of the degron tag and / or zinc finger polypeptide according to the invention is any one of SEQ ID 1-10, SEQ ID 11-20, SEQ ID 21-30, SEQ ID 31-40, SEQ ID 41-50, SEQ ID 51-60, SEQ ID 61-70, SEQ ID 71-80, SEQ ID 81-90, or SEQ ID 91-100, or SEQ ID NO: 135. In yet another embodiment, Figure 3 The first hybrid zinc finger domain (ZFP91ZF4-IKZF1ZF2) shown is replaced by any one of the sequences listed in Table 5.

[0197] Although for the present invention it is not necessary to include a second zinc finger domain, or a second hybrid zinc finger domain (as discussed below) in the degron tag and / or zinc finger polypeptide according to the invention, it was surprisingly found that the sensitivity of the degron tag and / or zinc finger polypeptide according to the invention can be further enhanced or increased by combining a first hybrid zinc finger domain (e.g. having at least two substitutions) with an additional second zinc finger domain, preferably a second hybrid zinc finger domain as described herein. Although different second zinc finger domains and / or second hybrid zinc finger domains can be used (as discussed elsewhere herein: for example, those obtained from IKZF1 ZF3, IKZF3 ZF3, ZFP91 ZF5, ZNF653 ZF5, ZNF276 ZF5, ZNF827 ZF2, ZNF692 ZF5 (see also Uniprot Accession Nos.: Q13422, Q9UKT9, Q96JP5, Q96CK0, Q8N554, Q17R98, Q9BU19, respectively), in a preferred embodiment, a degron tag and / or hybrid zinc finger polypeptide according to the invention is provided, and wherein the third part of the second hybrid zinc finger domain comprises the amino acid sequence according to SEQ ID NO: 104 (FKCHLCNYACRR), the fourth part of the second hybrid zinc finger domain comprises the amino acid sequence according to SEQ ID NO: 105 (FKCHLCNYACRR), NO:105 (KDSVVAHKAKSH), and / or wherein the second hybrid zinc finger comprises the amino acid sequence according to SEQ ID NO:106 (FKCHLCNYACRRKDSVVAHKAKSH). In a preferred embodiment, with respect to the second hybrid zinc finger, the second hybrid zinc finger is composed of a β-hairpin portion of IKZF1 ZF3 and an α-helical portion of ZFP91 ZF5.

[0198] According to another aspect of the present invention, the first part and / or the second part of the first hybrid zinc finger domain are obtained from the first Cys2-His2 zinc finger domain and / or the second Cys2-His2 zinc finger domain, and are IMiD substrates in natural proteins having the first Cys2-His2 zinc finger domain and / or the second Cys2-His2 zinc finger domain. Preferably, the first part and the second part of the first hybrid zinc finger domain are obtained from the first Cys2-His2 zinc finger domain and the second Cys2-His2 zinc finger domain, and both are IMiD substrates in natural proteins having the first Cys2-His2 zinc finger domain and the second Cys2-His2 zinc finger domain.

[0199] According to another aspect of the present invention, the first part and / or the second part of the first hybrid zinc finger domain are preferably obtained from the first Cys2-His2 zinc finger domain and / or the second Cys2-His2 zinc finger domain, which are IMiD substrates in natural proteins having the first Cys2-His2 zinc finger domain and / or the second Cys2-His2 zinc finger domain. Preferably, the first part and the second part of the first hybrid zinc finger domain are obtained from the first Cys2-His2 zinc finger domain and the second Cys2-His2 zinc finger domain, which are both IMiD substrates in natural proteins having the first Cys2-His2 zinc finger domain and the second Cys2-His2 zinc finger domain. According to the present invention, and according to this aspect, in a preferred embodiment, the third part and / or the fourth part of the second (hybrid) zinc finger domain (wherein "(hybrid) zinc finger domain" in the present invention means either of these two options, i.e., the second hybrid zinc finger domain or the second zinc finger domain) is the N-terminus or C-terminus, preferably the C-terminus, of the Cys2-His2 zinc finger domain of the third Cys2-His2 zinc finger domain and / or the fourth Cys2-His2 zinc finger domain as an IMiD substrate in a natural protein. In certain embodiments, the third part and / or the fourth part is obtained from a Cys2-His2 zinc finger domain that is not an IMiD substrate in a natural protein having the zinc finger domain.

[0200] Finally, as already discussed herein, a degron tag and / or a hybrid zinc finger polypeptide according to the invention is provided in the context of a linker peptide between a first hybrid zinc finger domain and a second hybrid zinc finger domain, wherein the first hybrid zinc finger domain and the second zinc finger domain, preferably the second hybrid zinc finger domain, are adjacent or connected via a linker peptide, e.g. comprising 1, 2, 3, 4, 5, 6, 7 or more amino acids. However, in some embodiments no additional linker peptide is present.

[0201] According to another aspect, not only is provided a degron tag according to the invention, which comprises a first hybrid zinc finger domain, further comprises at least two amino acid substitutions and comprises a second hybrid zinc finger domain. According to this aspect of the invention, there is also provided a non-natural hybrid zinc finger polypeptide, which comprises a first hybrid zinc finger domain, wherein the first hybrid zinc finger domain comprises a first part and a second part, wherein

[0202] (1) The first part contains the amino acid sequence X1X2C3X4X5C6X7X8X9X 10 X 11 , wherein X represents any amino acid of the first Cys2-His2 zinc finger domain;

[0203] (2) The second part contains the amino acid sequence X 12 X13 X 14 X 15 X 16 X 17 X 18 H 19 X 20 X 21 X 22 H 23 , wherein X represents any amino acid of a second Cys2-His2 zinc finger domain, wherein the second Cys2-His2 zinc finger domain is different from the first Cys2-His2 zinc finger domain;

[0204] (3) the second portion is C-terminal relative to the first portion; and

[0205] (4) wherein the first and second portions together comprise at least two amino acid substitutions, wherein the amino acid substitution in the first portion is relative to the first portion of the first Cys2-His2 zinc finger domain, wherein the amino acid substitution in the second portion is relative to the second portion of the second Cys2-His2 zinc finger domain, wherein the substitution is not located at C3, C6, X7, H 19 or H 23 Any location in .

[0206] Although the experiments show the presence of a second zinc finger domain or a second hybrid zinc finger domain in the degradation determinant tag and / or zinc finger polypeptide according to the present invention, the experiments also clearly show that such a second zinc finger domain or a second hybrid zinc finger domain is not necessary or essential for providing enhanced or increased sensitivity to IMiDs. In other words, the inventors have also surprisingly determined that increased or enhanced sensitivity to IMiDs can be provided by providing a hybrid zinc finger polypeptide as described herein. The hybrid zinc finger polypeptide comprises or consists of a first hybrid zinc finger domain that has been described in great detail herein, for example in the context of the degradation determinant tag according to the present invention. Therefore, the skilled person will understand that all aspects, preferences and features (e.g., size, position and type of substitution (e.g., Tables 1-6), sequence, linker, etc.) set forth in detail herein also apply to this aspect of the present invention and do not need to be repeated in full detail.

[0207] In a preferred embodiment of the present invention, the hybrid zinc finger polypeptide comprises any one of the sequences listed in Table 5. In certain embodiments, the hybrid zinc finger polypeptide according to the present invention comprises any one of the sequences listed in Table 5, preferably any one of SEQ ID 1-90, SEQ ID 1-80, SEQ ID 1-70, SEQ ID 1-60, SEQ ID 1-50, SEQ ID 1-40, SEQ ID 1-30, SEQ ID 1-20, SEQ ID 1-10, or SEQ ID NO: 135. In another embodiment, the zinc finger polypeptide according to the present invention comprises any one of SEQ ID 1-10, SEQ ID 11-20, SEQ ID 21-30, SEQ ID 31-40, SEQ ID 41-50, SEQ ID 51-60, SEQ ID 61-70, SEQ ID 71-80, SEQ ID 81-90, or SEQ ID 91-100, or SEQ ID NO: 135.

[0208] In an embodiment, a non-natural hybrid zinc finger polypeptide according to the invention is provided, and wherein the non-natural hybrid zinc finger comprises a first hybrid zinc finger domain as defined herein.

[0209] Also provided is a non-natural hybrid zinc finger polypeptide according to the present invention, which further comprises a second zinc finger domain, wherein the second zinc finger domain is a non-hybrid zinc finger domain. As explained herein, although it may be beneficial to include a second zinc finger domain in a hybrid zinc finger polypeptide according to the present invention, it has been determined that such a second zinc finger domain is not required to provide the observed enhanced or increased sensitivity to IMiDs. However, in certain embodiments, the non-natural hybrid zinc finger polypeptide according to the present invention further comprises a second zinc finger domain, wherein the second zinc finger domain is a non-hybrid zinc finger domain. For example, the second zinc finger domain may be a wild-type Cys2-His2 zinc finger domain, such as those disclosed herein, such as IKZF1ZF3, IKZF3 ZF3, and ZFP91 ZF5, ZNF653 ZF5, ZNF276ZF5 and / or ZNF827 ZF2, ZNF692 ZF5.

[0210] The second zinc finger domain is preferably oriented C-terminally relative to the first hybrid zinc finger domain and may be directly adjacent to or may be linked to the first hybrid zinc finger domain, as described elsewhere herein.

[0211] In certain embodiments, the second zinc finger domain is a second hybrid zinc finger domain, such as those described elsewhere herein. In those embodiments, wherein the second zinc finger domain in the hybrid zinc finger domain according to the invention is non-hybrid, such as a wild-type or naturally occurring zinc finger domain or a variant thereof, the second zinc finger domain is preferably selected from, for example, IKZF1 ZF3 (SEQ ID NO: 109 (FKCHLCNYACRRRDALTGHLRTH) or KZF3 ZF3 (SEQ ID NO: 110 (FKCHLCNYACQRRDALTGHLRTH) or comprises an amino acid sequence according to SEQ ID NO: 109 or SEQ ID NO: 110. Further examples of suitable second zinc finger domains include, for example, IKZF1 ZF3, IKZF3 ZF3, ZFP91 ZF5, ZNF653ZF5, ZNF276 ZF5, ZNF827ZF2, ZNF692 ZF5, SEQ ID NO: 109-115, etc.

[0212] According to another aspect, if a fusion protein containing a degron tag according to the invention, or a non-natural hybrid zinc finger polypeptide according to the invention is provided, it further comprises a protein of interest. This aspect of the invention relates to a fusion protein comprising a protein of interest (POI) and a degron tag or a hybrid zinc finger polypeptide according to the invention, which fusion protein can mediate the degradation of the POI comprising the fusion protein associated with the use of an IMiD.

[0213] In certain embodiments, the degron tag of the hybrid zinc finger polypeptide may be located at the N-terminus, C-terminus, or within the POI.

[0214] The fusion protein according to the present invention can be used in a method for degrading a target protein, and it includes contacting a cell expressing the fusion protein with an effective amount of IMiD. The target protein can be any suitable protein (of its fragment). In certain embodiments, the target protein is an endogenous protein. In certain embodiments, the target protein is an exogenous protein. In certain embodiments, the target protein is a recombinant protein or a non-natural protein. In certain embodiments, the target protein is a naturally occurring protein. Therefore, the degradation determinant tag and / or hybrid zinc finger protein of the present invention can be used to prepare, for example, an endogenous protein-degradation determinant tag fusion protein or an exogenous protein-degradation determinant tag fusion protein stably expressed in a cell. Endogenous proteins originate from organisms, tissues or cells and are expressed in the same organism, tissue or cell, while exogenous proteins originate from organisms, tissues or cells outside and are introduced into the organisms, tissues or cells.

[0215] Although the target protein in the fusion protein according to the present invention is not particularly limited to any particular type of protein, suitable examples of target proteins include, for example, Cbl-b, SOCS1, CISH, Tox, Eomes, IL12, IL15. CBL-B is an E3 ubiquitin protein ligase encoded by the CBLB gene in humans. SOCS family proteins form part of the classical negative feedback system that regulates cytokine signal transduction. SOCS1 participates in the negative regulation of cytokines through the signal transduction of the JAK / STAT signaling pathway. By binding to JAK and IFNGR1, its kinase activity is inhibited. In vitro, Tec protein-tyrosine activity is also inhibited. Cytokine-induced SH2-containing protein (CISH) is a human protein encoded by the CISH gene, which controls T cell receptor (TCR) signal transduction and comprises an SH2 domain and a SOCS box domain. Thymocyte selection-related high mobility group box protein TOX is a human protein encoded by the TOX gene. TOX drives T cell exhaustion and plays a role in the development of innate lymphoid cells. Eomesodermin, also known as T-box brain protein 2 (Tbr2), is a human protein encoded by the EOMES gene. Eomesodermin / Tbr2 is highly expressed in CD8+ T cells but not in CD4+ T cells. Interleukin 12 (IL-12) is an interleukin produced naturally by dendritic cells, macrophages, neutrophils, and human B-lymphoblastoid cells (NC-37) in response to antigenic stimulation. Interleukin-15 (IL-15) is a cytokine that binds and signals through a complex consisting of the IL-2 / IL-15 receptor β chain (CD122) and the common γ chain (γ-C, CD132). IL-15 is secreted by mononuclear phagocytes (and some other cells) after viral infection and induces the proliferation of natural killer cells.

[0216] Other target proteins include, for example, such chimeric polypeptides as described in WO2021080427, which allow, for example, signaling by T cell receptor (TCR) and / or chimeric antigen receptor (CAR) to regulate T cell activity in time and / or dose-dependent manner, and signaling by NK cell receptor (NKR) and / or chimeric antigen receptor (CAR) to regulate NK cell activity in time and / or dose-dependent manner. Chimeric polypeptides as described herein are designed to interact with phosphorylated immunoreceptor tyrosine-based activation motifs (ITAMs) in TCR / CD3 complexes and / or CAR and / or NK cell receptor (NKR) complexes containing ITAM, and the ITAM contains signaling molecules such as DAP12, immunoglobulin receptor FceRI's γ chain or CD3's ζ chain (Lanier et al, Nat Immunol.2008May; 9(5): 495-502).

[0217] The chimeric polypeptide of WO2021080427 provides strict regulation of T cell and NK cell activity (e.g., cytotoxic activity and / or cytokine secretion) due to the presence of a small molecule regulatory protein stabilizing domain for regulating (e.g., reducing or increasing) the expression of the chimeric polypeptide in a time and / or dose-dependent manner. In a preferred embodiment of the present invention, this / small molecule regulated protein stabilizing domain is a degradation determinant tag and / or a hybrid zinc finger polypeptide according to the present invention. The target protein is a protein as disclosed in detail in WO202102080427, comprising a first part, the first part containing an SH2 domain, the SH2 domain from a protein (ITAM) bound to an activation motif based on phosphorylated immunoreceptor tyrosine, preferably also comprising a second part, the second part containing an immunoreceptor tyrosine-based switch motif (ITSM), preferably ITSM and an immunoreceptor tyrosine-based inhibitory motif (ITIM). The protein is preferably combined with a third part comprising a small molecule regulatory protein stabilizing domain, which is a degradation determinant tag or a hybrid zinc finger polypeptide as disclosed herein according to the present invention. In certain embodiments, ITAM is an ITAM included in a T cell receptor (TCR) complex and / or a NK cell receptor (NKR) complex and / or a chimeric antigen receptor (CAR), and preferred ITAMs are derived from CD3ζ chains, CD3ε chains, CD3δ chains, CD3γ chains, immunoglobulin receptor FceRI and the γ chain of DAP12. In certain embodiments, the SH2-domain is from a protein selected from the group consisting of Zap70, Syk and Lck. In certain embodiments, the chimeric polypeptide includes more than one SH2 domain from a protein that binds to an activation motif of a phosphorylated immunoreceptor tyrosine. In certain embodiments, ITIM and / or ITSM are from inhibitory receptor proteins, preferably inhibitory immune receptor proteins, preferably from a protein selected from the group consisting of PD1, BTLA, SIRPα, SIGLEC5, SIGLEC9, SIGLEC11, PECAM1 or LY9.

[0218] Also provided is a non-naturally occurring nucleic acid encoding a degron tag according to the invention, a non-naturally occurring hybrid zinc finger polypeptide according to the invention or a fusion protein according to the invention.

[0219] Also provided are vectors comprising such non-naturally occurring nucleic acids.

[0220] Also provided are cells or host cells expressing the non-naturally occurring nucleic acid according to the invention. Preferably, the cells, host cells, target protein and / or Cys2-His2 zinc finger domain or zinc finger domain, and other sequences in the degron tag and / or hybrid zinc finger polynucleotide according to the invention are human or derived from human or consist essentially of human sequences.

[0221] According to another aspect of the present invention, there is provided a method for providing a degron tag according to the present invention, a non-natural hybrid zinc finger polypeptide according to the present invention, a fusion protein according to the present invention or a nucleic acid encoding these, the method comprising

[0222] (A) providing a hybrid zinc finger domain comprising a first portion and a second portion, wherein:

[0223] (1) The first part contains the amino acid sequence X1X2C3X4X5C6X7X8X9X 10 X 11 , wherein X represents any amino acid of the first Cys2-His2 zinc finger domain;

[0224] (2) The second part contains the amino acid sequence X 12 X 13 X 14 X 15 X 16 X 17 X 18 H 19 X 20 X 21 X 22 H 23 , wherein X represents any amino acid of a second Cys2-His2 zinc finger domain, wherein the second Cys2-His2 zinc finger domain is different from the first Cys2-His2 zinc finger domain;

[0225] (3) the second portion is C-terminal relative to the first portion;

[0226] (B) introducing at least two different amino acid substitutions into the hybrid zinc finger domain, wherein the substitutions are not in C3, C6, X7, H 19 or H 23 Any position in

[0227] (C) using the hybrid zinc finger domain obtained in step (B) or the nucleic acid sequence encoding the hybrid zinc finger domain obtained in step (B) to prepare a degron tag according to the present invention, a non-natural hybrid zinc finger polypeptide according to the present invention, a fusion protein according to any one of the inventions, or a nucleic acid encoding these.

[0228] The skilled person is well aware of methods allowing the preparation of a degron tag according to the invention, a non-natural hybrid zinc finger polypeptide according to the invention, a fusion protein according to the invention or nucleic acids encoding these. Such methods are readily available in the prior art and include, for example, those described in the examples.

[0229] The skilled person will also understand that with respect to the first part, the second part, and with respect to the first and second Cys2-His2 zinc finger domains, the same considerations, features and preferences apply as those described in other parts of the invention.

[0230] The skilled person will also understand that for the at least two different amino acid substitutions introduced in the method of the present invention, this can be located at any position of the hybrid zinc finger domain including the first part and the second part, and the substitution can be introduced into any amino acid (as long as the substituted amino acid is different from the replacing amino acid). The skilled person will also understand that in a preferred embodiment, the position, the substituted amino acid and / or the substituted amino acid are as described in any one of Tables 1-6 and 8, including combinations of at least two substitutions and preferably as shown.

[0231] The method may comprise the step of testing a hybrid zinc finger domain comprising at least two substitutions, and / or a degron tag according to the invention, a non-natural hybrid zinc finger polypeptide according to the invention, a fusion protein according to the invention or nucleic acids encoding these, e.g., using the method of the invention to obtain sensitivity to IMiDs, e.g. as described in the Examples, e.g. by determining an EI value or index as described herein.

[0232] According to the EI value or index, it can be decided whether the obtained hybrid zinc finger domain comprises at least two substitutions, and / or whether the degron tag according to the invention, the non-natural hybrid zinc finger polypeptide according to the invention, the fusion protein according to the invention or the nucleic acid encoding these should be discarded. Therefore, in a preferred embodiment, the method comprises a step of analyzing the obtained hybrid zinc finger domain comprising at least two substitutions, and / or the degron tag according to the invention, the non-natural hybrid zinc finger polypeptide according to the invention, the fusion protein according to the invention or the nucleic acid encoding these for sensitivity to IMiDs, for example as described in the Examples section, to determine its use as a degron, etc.

[0233] Thus, embodiments are provided for establishing the sensitivity of a degron tag according to the invention, a non-natural hybrid zinc finger polypeptide according to the invention, a fusion protein according to the invention to immunomodulatory imine drug (IMiD)-induced degradation, e.g. obtained by a method according to the invention, preferably wherein the IMiD is selected from thalidomide, lenalidomide, pomalidomide, avalidomide, ibromid, salts thereof and analogs thereof.

[0234] Therefore, the degron tag according to the invention, the non-natural hybrid zinc finger polypeptide according to the invention, the fusion protein according to the invention can be selected according to its ability to be induced by a specific small molecule, preferably an immunomodulatory inducing drug (IMiD). In one aspect, the IMiD is thalidomide or one of its analogs, such as lenalidomide, pomalidomide, avalidomide or ibrolidomide.

[0235] According to another aspect, a method for degrading a target protein or for controlling the expression of a target protein is provided, comprising contacting a cell in vitro or in vivo with an effective amount of an IMiD, wherein the cell expresses a nucleic acid encoding a degradation determinant tag according to the present invention and / or a non-natural hybrid zinc finger polypeptide according to the present invention, or a fusion protein according to the present invention, preferably wherein the method is used to modulate the activity of the target protein.

[0236] According to another aspect, a method for degrading a target protein or for controlling the expression of a target protein is provided, comprising administering an effective amount of an IMiD to a subject (preferably a human subject), wherein the subject has previously been treated by gene therapy, causing at least some cells in the subject to express a nucleic acid encoding a degradation determinant tag according to the present invention, a non-natural hybrid zinc finger polypeptide according to the present invention, or a fusion protein according to the present invention, preferably comprising a target protein. In a preferred embodiment, the method is a method in which the gene therapy comprises introducing cells into the subject (e.g., T cells, B cells, or NK cells), wherein the introduced cells express a nucleic acid encoding a degradation determinant tag according to the present invention, a non-natural hybrid zinc finger polypeptide according to the present invention, or a fusion protein according to the present invention, e.g., comprising a target protein.

[0237] These aspects of the invention relate to methods of degrading a protein of interest and the methods comprise, for example, contacting a transgenic cell with an effective amount of an IMiD, wherein the cell, for example, produces a fusion protein comprising the protein of interest and at least one degron tag and / or hybrid zinc finger polynucleotide according to the invention.

[0238] The method can be performed in vivo or in vitro. The POI can be exogenous or endogenous. The ability to degrade specific endogenous or exogenous target proteins by creating a POI-degradation determinant tag fusion and administering an IMiD can be used to treat diseases by controlling cell behavior, for example as described in WO2021080427.

[0239] Therefore, the degradation determinant tag, hybrid zinc finger polynucleotide and fusion protein of the present invention can be used to prepare stably expressed endogenous protein-degradation determinant tag fusion protein or exogenous protein-degradation determinant tag fusion protein, and its level or cellular activity can be regulated by providing IMiDs to cells expressing such fusion protein or removing IMiDs from cells expressing such fusion protein.

[0240] Also provided is the use of a nucleic acid encoding a degron tag according to the invention, a non-natural hybrid zinc finger polypeptide according to the invention, or a fusion protein according to the invention in treating a subject (preferably a human subject). The treatment of a patient in need of treatment may be as described herein, or may be any other treatment.

[0241] Therefore, the present invention also provides the use of a degradation determinant tag according to the present invention, a non-natural hybrid zinc finger polypeptide according to the present invention, a fusion protein according to the present invention or a nucleic acid encoding any of these in controlling transcription factors such as Eomes, Tox, negative regulators of TCR signal transduction such as Cbl-b, negative regulators of cytokine receptors such as SOCS1, CISH, membrane-bound cytokines such as IL12, IL15, antigen receptors such as TCR, CAR, NKR, checkpoint receptors such as PD1, LAG3, TIM3, nucleases such as Cas9, TALEN or zinc finger nucleases.

[0242] Also provided is a first hybrid zinc finger domain and / or a second hybrid zinc finger domain as disclosed herein.

[0243] The present invention also provides the use of a degron tag according to the invention, a non-natural hybrid zinc finger polypeptide according to the invention, a fusion protein according to the invention, a first hybrid zinc finger domain according to the invention, a second hybrid zinc finger domain according to the invention, or a nucleic acid encoding any of these as a medicament, preferably as a medicament in combination with the use of an IMiD. Pharmaceutical compositions comprising a degron tag according to the invention, a non-natural hybrid zinc finger polypeptide according to the invention, a fusion protein according to the invention, a first hybrid zinc finger domain according to the invention, a second hybrid zinc finger domain according to the invention, or a nucleic acid encoding any of these, including in combination with an IMiD.

[0244] In one aspect, the degron tag according to the invention, the non-natural hybrid zinc finger polypeptide according to the invention or the fusion protein according to the invention has an enhanced or increased sensitivity to IMiD molecules, such as thalidomide analogs, relative to, for example, a wild-type zinc finger domain.

[0245] In one aspect, the degron tag according to the invention, the non-natural hybrid zinc finger polypeptide according to the invention or the fusion protein according to the invention has an enhanced or increased sensitivity to one or more IMiD molecules relative to the wild-type Cys2-His2 zinc finger domain from which the β-hairpin and / or α-helical subdomain is derived.

[0246] In one embodiment, the enhanced or increased sensitivity to one or more IMiD molecules allows the amount of the administered IMiD molecule to be reduced to induce degradation by 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80% or more. In one aspect, the amount of small molecules, such as IMiD molecules, administered is reduced by 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 50, 100, 110, 120, 130, 140, 150 or more times.

[0247] The foregoing description of the specific embodiments will fully reveal the general nature of the present invention, and others can easily modify and / or adjust the various applications of such specific embodiments by applying knowledge within the technical scope of the art (including the contents of the references cited in the present invention) without excessive experimentation and without departing from the general concept of the present invention. Therefore, based on the teachings and guidance proposed by the present invention, such adjustments and modifications are intended to be within the meaning and scope of equivalents of the disclosed embodiments.

[0248] All references cited herein, including journal articles or abstracts, published or corresponding patent applications, patents, or any other references, are fully incorporated into the present invention by reference, including all data, tables, figures, and text presented in the cited references. In addition, the entire contents of the references cited in the references cited herein are also fully incorporated by reference.

[0249] It should be understood that the terms and expressions used herein are for the purpose of description rather than limitation, and the terms and expressions of this specification will be understood by technicians based on the teachings and guidance provided by the present invention and in combination with the knowledge of those skilled in the art.

[0250] It should be understood that all details, embodiments and preferences discussed with respect to one aspect of an embodiment of the present invention are also applicable to any other aspect or embodiment of the present invention, and therefore it is not necessary to describe all said details, embodiments and preferences in detail for all aspects respectively.

[0251] Having now generally described the invention, it will be more readily understood by reference to the following examples, which are provided by way of illustration and are not intended to limit the invention.Other aspects and embodiments will be apparent to those skilled in the art. Example

[0252] Due to concerns associated with the use of higher doses of IMiDs, identification of novel zinc finger degradation determinant sequences that can be regulated at lower drug doses is needed. In previous work (Sievers et al. Science. 2018 Nov 2; 362(6414): eaat0572), hybrid zinc finger sequences were described that combined β-hairpins and α-helices from two different zinc finger degradation determinants, which showed increased sensitivity to MiD-induced degradation compared to the parent zinc finger degradation determinants.

[0253] Specifically, a hybrid zinc finger degron containing the ZFP91 ZF4 β-hairpin and the IKZF1 ZF2 α-helix exhibited increased sensitivity to IMiD-induced degradation compared to non-hybrid ZFP91 ZF4 and IKZF1 ZF2 zinc finger degrons. We previously created the ZFP91 ZF4 β-hairpin-IKZF1 ZF2 α-helix-IKZF1 ZF3 degron (abbreviated as single hybrid dual zinc finger prior art degron, Figure 1 ), and demonstrated that the CRASH-IT switch design containing this single hybrid dual zinc finger prior art degron domain can be regulated by IMiD molecules (WO2021080427A1). Here, we identified novel zinc finger-based degron domains that contain modifications in the first and preferably second zinc finger motifs of the degron tag and showed significantly improved responses to lower drug concentrations. Based on these data, we propose these new degron domains, called synthetic zinc fingers (SynFingers), as optimal building blocks for controlling the abundance of target proteins.

[0254] Example 1

[0255] Materials and methods

[0256] Cell lines and cell culture

[0257] FLYRD18 (Sigma-Aldrich), NKIRTIL006 (Kvistborg et al. Oncoimmunology. 2012 Jul 1; 1(4): 409-418) and Jurkat cells were cultured in IMDM (ThermoFisher) supplemented with 8% FCS (ThermoFisher) and penicillin-streptomycin (100 IU / ml penicillin, 100 μg / ml streptomycin, Sigma-Aldrich). FLYRD18 and NKIRTIL006 cells were passaged every 2-3 days using trypsin-EDTA (ThermoFisher). All cell lines were tested for mycoplasma using PCR-based screening, and the results were negative.

[0258] Preparation of retrovirus

[0259] Retroviral particles were produced in FLYRD18 packaging cells. Briefly, 700,000 FLYRD18 packaging cells were inoculated per 10 cm dish one day before transfection. The next day, the cell culture medium was updated with IMDM supplemented with 8% FCS without antibiotics. 25 μl of X-tremeGENE 9 (Roche) was mixed with 800 μl of Opti-MEM (ThermoFisher) and incubated for 5 min. Subsequently, the Optimem-X-tremeGENE 9 mixture was added to 10 μg of retroviral plasmid DNA dissolved in water, incubated for 15 minutes, and the resulting transfection mixture was then added dropwise to the packaging cells. The supernatant containing the retrovirus was collected 48 hours after transfection and used immediately or quickly frozen in liquid nitrogen.

[0260] Plasmids

[0261] Retroviral vectors encoding CRASH-IT containing a single-hybrid dual zinc finger prior art degradation determinant (pMP71-Zap70 2xSH2-PD1-ZFP91 ZF4β hairpin-IKZF1 ZF2α helix-IKZF1 ZF3 iresEGFP, WO2021080427A1), a CRASH-IT variant containing a single-hybrid single zinc finger degradation determinant (pMP71-Zap70 2xSH2-PD1-(ZFP91 ZF4β hairpin-IKZF1ZF2α helix iresEGFP, WO2021080427A1) and an HLA class I restricted CDK4 TCR (TCR 17, Stronen et al, Science. 2016 Jun 10; 352(6291):1337-41) have been previously described.

[0262] The Gibson assembly method was used to replace the IKZF1 ZF3α helix coding sequence in the pMP71-Zap70 2xSH2-PD1-ZFP91 ZF4β hairpin-IKZF1 ZF2α helix-IKZF1 ZF3 iresEGFP vector with a gene synthesis product encoding the ZFP91 ZF5α helix sequence (IDT, IA, USA) (Gibson et al. Nat Methods. 2009 May; 6(5): 343-5). The resulting degron is called a "double hybrid degron" ( Figure 3 ).

[0263] Twist Biosciences (CA, USA) synthesized a highly diverse SynFinger library (~50,200 variants) using the combinatorial variant library service, such as Figure 3As shown. pMP71-Zap70-Siglec11-FKBP12F36ViresEGFP has been described previously (Sahillioglu et al. Hum Gene Ther. 2021Oct; 32(19-20): 1029-1043). The FKBP12F36V coding sequence in this vector was replaced by a gene encoding a double hybrid degradation determinant ( Figure 3 ) or a gene synthesis product encoding a double hybrid degron variant containing a G14N / K21A, G14M / N15R, L17I / K21L, E4R / Q12L, Q12R / K1T or Q12R / K13V double substitution, or a Q12R / K13V / G14N / K21A quadruple substitution (SED ID NO: 135; SEQ ID NO: 136).

[0264] filter

[0265] Twist Biosciences performed quality control on the SynFinger libraries. Figure 3 Of the approximately 50,200 synthetic sequences shown, all but two SynFinger sequences were observed in the clone library. 150 billion Jurkat cells were transduced with the SynFinger library (SynFinger with CRASH-IT switch) at a transduction efficiency of 12.8% and cells with high EGFP expression were sorted to enrich for transduced cells. For quality control of SynFinger transduced Jurkat cells, SynFinger sequences were amplified and analyzed by NGS. Ten randomly selected SynFinger encoding DNA sequences or DNA sequences encoding the same SynFinger amino acid sequence but containing two nucleotide mismatches due to alternative codon usage were used to assess the ability to distinguish true SynFinger sequences from noise in the NGS data. 10 / 10 SynFinger encoding full nucleotide sequence matches were observed in the NGS data, while the sequence containing two nucleotide mismatches was not detected.

[0266] Jurkat cells expressing the SynFinger library were treated with 50 nM lenalidomide (a suboptimal dose that activated only about 50% of cells expressing the CRASH-IT switch containing the parental two-hybrid degron in Jurkat cells compared to the maximally effective dose of 1000 nM lenalidomide) or mock-treated for 24 hours, followed by activation with anti-CD3 / anti-CD28 antibodies for 5 hours in the presence or absence of 50 nM lenalidomide. Cells were stained with IR dye (1:400) and anti-CD69-PE (1:200). Live cells (negative for IR dye), EGFP high-CD69 high expression (top 5%) or CD69 low expression (bottom 5%) were sorted using an Aria Fusion cell analyzer.

[0267] Subsequently, the cells were washed with PBS and the cell pellets were frozen at -20°C until DNA extraction. Genomic DNA was isolated using the DNeasy Blood and Tissue Kit (Qiagen) according to the manufacturer's instructions, using 5 × 10 ^6 cells. DNA was eluted with 22 μl RNAse-free water. Deep sequencing adapters and indexes were added to the SynFinger-encoded DNA sequences using PCR amplification. Briefly, 3 μg genomic DNA (20 ul), index forward and reverse primers (10 μM, 2.5 μl each) and 25 μl High-fidelity 2X PCR Master Mix was added to the PCR reaction. The optimized PCR reaction was performed using an Eppendorf PCR cycler (98°C for 30 s, (98°C for 10 s, 56°C for 10 s, 72°C for 5 s) x 25 cycles, 72°C for 3 minutes.

[0268] Index PCR products were run on agarose gels, relative DNA concentrations were estimated by measuring band intensities, and 12 index PCR reaction products were mixed per MiSeq chip. To increase sequence diversity, samples were mixed with 25% PhiX DNA. A total of 2 MiSeq chips (100 bp, single read) were used. To distinguish true SynFinger sequences from sequencing errors, results were filtered using the actual sequence reference list used in SynFinger library design (codon 100% match). Sequences with very low read counts (sum of all samples with read counts below 500) were excluded from the analysis.

[0269] To identify SynFingers that increase the sensitivity of the CRASH-IT switch to lenalidomide while maintaining or increasing the stringency of switch-mediated control of T cell activation in the absence of lenalidomide, an enrichment index (EI) value was calculated for each sequence as described below, and SynFingers were ranked according to their EI, with a low EI indicating that the SynFinger has the desired properties.

[0270]

[0271] Using a two-sided Fisher's exact test, CD69-HI and CD60-LO read counts from the top 100 SynFingers were compared to read counts from the parental two-hybrid degron to determine the enrichment of CD69-HI cells in the presence of lenalidomide and the enrichment of CD69-LO cells in the absence of lenalidomide. The results for SEQ ID NOs: 1-100 are shown in Tables 6 and 9.

[0272] Table 9

[0273]

[0274]

[0275]

[0276] Example 2

[0277] result

[0278] To our knowledge, the possibility of using a hybrid zinc finger as the second zinc finger as a means to increase the overall sensitivity of a dual zinc finger degron system has not been tested before. To investigate whether the second zinc finger (IKZF1 ZF3) of a single hybrid dual zinc finger prior art degron could be replaced by other zinc finger sequences while maintaining or increasing sensitivity to IMiDs, we created a panel of CRASH-IT switches containing zinc finger degrons, such as Figure 1 As shown. Primary human T cells were transduced to express a CDK4 neoantigen-specific MHC class I-restricted TCR, and CRASH-IT variants encoding the indicated zinc finger degron. Analysis of cytokine production (IFNγ, IL2, and TNFα) and T cell degranulation (LAMP-1 surface expression) when co-cultured with NKIRTIL006 cells expressing the endogenous CDK4 neoantigen revealed that the dual-hybrid degron increased the sensitivity of the CRASH-IT switch to thalidomide compared to CRASH-IT variants containing single-hybrid, dual-zinc finger prior art degron sequences ( Figure 1 ).

[0279] Consistent with previous data, the CRASH-IT switch containing a single-hybrid, single-zinc-finger degron showed reduced thalidomide sensitivity compared to the prior art degron sequence containing a single-hybrid, dual-zinc-finger degron ( Figure 1 ).

[0280] To further improve the sensitivity of the two-hybrid degron to IMiDs, we performed a high-throughput screen using a library of approximately 50,200 CRASH-IT variants encoding single or double amino acid substitutions at the positions indicated in the sequence of the first hybrid zinc finger, thereby changing the 18 amino acids of this zinc finger to any amino acid except cysteine ​​( Figure 3 ). Jurkat T cells expressing synthetic zinc fingers (SynFingers) containing the CRASH-IT variant library were treated or not with low dose (50nM) lenalidomide for 24 hours and then stimulated with aCD3 / aCD28 antibodies for 5 hours in the continued presence or absence of lenalidomide. Subsequently, the 5% of Jurkat cells with the highest or lowest expression of the T cell activation marker CD69 were isolated by FACS, and the SynFinger sequences present in these populations were amplified and NGS analyzed. The relative abundance of SynFinger sequences in the CD69-HI and CD69-LO populations was analyzed, and it was found that amino acid substitutions in the zinc finger domain increased sensitivity to IMiDs. The enrichment index (EI) value for each SynFinger, reflecting high expression of CD69 in the presence of lenalidomide and low expression of CD69 in the absence of lenalidomide, has been calculated (see Methods). SynFingers were then ranked according to their EI values ​​to identify novel zinc finger degrons with desirable features, such as increased sensitivity to IMiDs and efficient switch function in the absence of IMiDs (thus stabilizing POI expression).

[0281] The top 100 SynFingers identified using this method all contained double amino acid substitutions (Table 6). Importantly, certain amino acid substitutions, such as Q12R, Q12K, N15R, and L22R (present in 11%, 8%, 9%, and 6% of the top 100 SynFingers, respectively), were frequently observed in the top 100 SynFingers containing double substitution mutations ( Figure 4). It is noteworthy that the mutations also ranked high when analyzed as single amino acid substitutions. In addition, the frequently observed major amino acid substitutions Q12R, Q12K, N15R and L22R, when combined with the minor amino acid substitutions listed in Table 8, further increased the sensitivity to IMiDs in a synergistic manner (i.e., EI Q12R / K13V=0.006877267, and EI Q12R=0.167217557). Therefore, in particular, in a preferred embodiment of the present invention, a combination of amino acid substitutions mentioned in Table 8 is used / provided, such as 12R and 13T or 22R and 14L, etc.

[0282] Table 8 - Minor mutations observed in combination with the Q12R, N15R, Q12K and L22R major mutations in the top 100 list in Table 5

[0283]

[0284] To test whether SynFingers that showed improved drug sensitivity in the Jurkat SynFinger library screen also resulted in improved sensitivity to low IMiD concentrations when expressed in human primary T cells, human peripheral blood T cells were modified to express the CDK4 TCR and the SynFingers contained the CRASH-IT switch variant ( Figure 5 Importantly, T cells expressing SynFingers containing double substitutions of G14N / K21A, G14M / N15R, L17I / K21L, E4R / Q12L, Q12R / K1T, and Q12R / K13V showed improved cytokine production at very low (5 nM) lenalidomide concentration levels compared to T cells expressing the CRASH-IT switch containing the starting point of the gene selection for the formation of the two-hybrid degron ( Figure 5 ). In addition, small molecule titration experiments showed that for all T cell effector functions tested, SynFingers containing the Q12R / K13V dual substitutions had 5.3- to 7.4-fold lower EC50 values ​​compared to the CRASH-IT switch containing a single hybrid dual zinc finger prior art degron ( Figure 6 ).

[0285] Based on the identification of two groups of amino acid substitutions, such as Q12R / K13V and G14N / K21A, that enhanced the lenalidomide sensitivity of the SynFinger degron, we hypothesized that combinations of the groups could further improve drug sensitivity. To test this, we created CRASH-IT switch variants containing the parental ZF or SynFinger degrons with double substitutions (Q12R / K13V or G14N / K21A) or quadruple substitutions (Q12R / K13V / G14N / K21A; SEQ ID NO: 135 and SEQ ID NO: 136). Primary human T cells were transduced to express the CDK4 TCR, as well as the CRASH-IT variants shown. In co-culture with NKIRTIL006 cells expressing the endogenous CDK4 neoantigen, analysis of cytokine production (IFNγ, IL2, and TNFα) and T cell degranulation (LAMP-1 surface expression) demonstrated that the combination of Q12R / K13V / G14N / K21A substitutions increased the sensitivity of SynFinger to lenalidomide compared with SynFinger degron containing Q12R / K13V or G14N / K21A ( Figure 7 ).

[0286] Thus, these data identify specific positions and mutations in zinc finger sequences that generate improved substrates that can be regulated by IMiDs, as well as specific combinations of amino acid mutations that generate such improved substrates. Note that in the SynFinger validation experiments ( Figure 5 and Figure 6 ), used a CRASH-IT variant containing the Siglec11 signaling domain, and in a high-throughput SynFinger library screen ( Figure 3 and Figure 4 ), used a CRASH-IT variant containing the PD1 signaling domain and showed that optimized SynFingers improved control of cellular function independent of the POI effector domain.

[0287] The synthetic zinc finger (SynFinger) sequence we identified in this study can be used in a range of applications in addition to its use in the CRASH-IT switch platform. For example, important regulators of cellular function, such as receptors that determine antigen specificity of immune cells, as well as control antigen sensitivity, cytokine signaling or cell differentiation can be modulated by creating fusion proteins with this novel SynFinger sequence. The ability to induce protein degradation at reduced IMiD levels opens new possibilities for applying this protein degradation technology to clinical cell therapy and other fields.

Claims

1. A degradation determinant tag comprising a non-native first hybrid zinc finger domain and a non-native second hybrid zinc finger domain, wherein (1) the first hybrid zinc finger domain comprises a first part and a second part; (2) The first part comprises the amino acid sequence X1X2C3X4X5C6X7X8X9X 10 X 11 , wherein X represents any amino acid of the first Cys2-His2 zinc finger domain; (3) The second part comprises the amino acid sequence X 12 X 13 X 14 X 15 X 16 X 17 X 18 H 19 X 20 X 21 X 22 H 23 , wherein X represents any amino acid of a second Cys2-His2 zinc finger domain, wherein the second Cys2-His2 zinc finger domain is different from the first Cys2-His2 zinc finger domain; (4) the second portion is C-terminal relative to the first portion; (5) the second hybrid zinc finger domain is C-terminal relative to the first hybrid zinc finger domain; (6) the second hybrid zinc finger domain comprises a third part and a fourth part; (7) The third part comprises the amino acid sequence (Z)2C(Z)2C(Z) 5-6 , wherein Z represents any amino acid of the third Cys2-His2 zinc finger domain; (8) The fourth second part comprises the amino acid sequence (Z)6H(Z) 3-4 H, wherein Z represents any amino acid of a fourth Cys2-His2 zinc finger domain, wherein the fourth Cys2-His2 zinc finger domain is different from the third Cys2-His2 zinc finger domain; and (9) the fourth portion is C-terminal relative to the third portion; and (10) wherein the first hybrid zinc finger domain comprises at least two amino acid substitutions, wherein the amino acid substitutions in the first portion of the first hybrid zinc finger domain are relative to the first portion of the first Cys2-His2 zinc finger domain, and wherein the amino acid substitutions in the second portion of the first hybrid zinc finger domain are relative to the second portion of the second Cys2-His2 zinc finger domain, wherein the substitutions are not located at C3, C6, X7, H 19 or H 23 Any position in .

2. The degron tag of any one of the preceding claims, wherein the degron tag is capable of binding to a complex formed between cereblon (CRBN) and an immunomodulatory drug (IMiD).

3. The degron tag of any one of the preceding claims, wherein The first portion is a β-hairpin loop of a first Cys2-His2 zinc finger domain, the second portion is an α-helical region of a second Cys2-His2 zinc finger domain, the third portion is a β-hairpin loop of a third Cys2-His2 zinc finger domain, and / or the fourth portion is an α-helical region of a fourth Cys2-His2 zinc finger domain.

4. The degron tag of any of the preceding claims, wherein the first substitution is in the second portion and the second substitution is in the first portion or in the second portion.

5. The degradation determinant tag of any of the preceding claims, wherein at least one substitution is in a region selected from the group consisting of X1, X4, X 12 , X 13 , X 14 , X 15 , X 17 , X 21 and X 22 The position in the group that is composed.

6. The degron signature of any of the preceding claims, wherein at least one substitution is selected from those listed in Table 1, preferably wherein at least two substitutions are each independently selected from those listed in Table 1.

7. The degron signature of any of the preceding claims, wherein at least two substitutions are selected from those listed in Table 2.

8. The degron tag of any of the preceding claims, wherein the amino acids in the substituted first portion and / or the amino acids in the substituted second portion are selected from those listed in Table 3.

9. The degron tag of any of the preceding claims, wherein the at least two amino acids substituted in the first part and / or in the second part are selected from those listed in Table 4.

10. The degron tag of any one of the preceding claims, wherein: (1) the first Cys2-His2 zinc finger domain is selected from the group consisting of IKZF1 ZF2, IKZF3 ZF2, ZFP91 ZF4, ZNF654ZF1, ZNF787 ZF5, ZNF653 ZF4, ZNF276 ZF4, ZNF692ZF4, ZNF582 ZF9, ZNF517 ZF10, E4F1ZF2 and ZNF827 ZF1, preferably ZFP91 ZF4; (2) the second Cys2-His2 zinc finger domain is selected from the group consisting of IKZF1 ZF2, IKZF3 ZF2, ZFP91 ZF4, ZNF654ZF1, ZNF787 ZF5, ZNF653 ZF4, ZNF276 ZF4, ZNF692ZF4, ZNF582 ZF9, ZNF517 ZF10, E4F1ZF2, and ZNF827 ZF1, preferably IKZF1 ZF2; (3) the third Cys2-His2 zinc finger domain is selected from the group consisting of IKZF1 ZF3, IKZF3 ZF3, ZFP91 ZF5, ZNF653ZF5, ZNF276 ZF5, ZNF827 ZF2, and ZNF692 ZF5, preferably IKZF1 ZF3; and / or (4) The fourth Cys2-His2 zinc finger domain is selected from the group consisting of IKZF1 ZF3, IKZF3 ZF3, ZFP91 ZF5, ZNF653ZF5, ZNF276 ZF5, ZNF827 ZF2, and ZNF692 ZF5, preferably ZFP91 ZF5.

11. The degron tag of any of the preceding claims, wherein at least two amino acid substitutions are introduced into a first hybrid zinc finger domain, the first part of which has an amino acid sequence according to SEQ ID NO: 101, and / or the second part of which has an amino acid sequence according to SEQ ID NO: 102, and / or the first hybrid zinc finger domain has an amino acid sequence according to SEQ ID NO:

103.

12. The degron tag of any of the preceding claims, wherein the first hybrid zinc finger domain comprising at least two substitutions is selected from those listed in Table 5.

13. The degron tag of any of the preceding claims, wherein the third portion of the second hybrid zinc finger domain comprises the amino acid sequence according to SEQ ID NO: 104, the fourth portion of the second hybrid zinc finger domain comprises the amino acid sequence according to SEQ ID NO: 105, and / or wherein the second hybrid zinc finger domain comprises the amino acid sequence according to SEQ ID NO:

106.

14. The degron tag of any of the preceding claims, wherein the first hybrid zinc finger domain is adjacent to the second hybrid zinc finger domain or is connected by a linker peptide.

15. A non-natural hybrid zinc finger polypeptide comprising a first hybrid zinc finger domain, wherein the first hybrid zinc finger domain comprises a first portion and a second portion, wherein (1) The first part comprises the amino acid sequence X1X2C3X4X5C6X7X8X9X 10 X 11 , wherein X represents any amino acid of the first Cys2-His2 zinc finger domain; (2) The second part comprises the amino acid sequence X 12 X 13 X 14 X 15 X 16 X 17 X 18 H 19 X 20 X 21 X 22 H 23 , wherein X represents any amino acid of a second Cys2-His2 zinc finger domain, wherein the second Cys2-His2 zinc finger domain is different from the first Cys2-His2 zinc finger domain; (3) the second portion is C-terminal relative to the first portion; and (4) Among them, The first and second portions together comprise at least two amino acid substitutions, wherein the amino acid substitutions in the first portion are relative to the first portion of the first Cys2-His2 zinc finger domain, wherein the amino acid substitutions in the second portion are relative to the second portion of the second Cys2-His2 zinc finger domain, wherein the substitutions are not located at C3, C6, X7, H 19 or H 23 Any position in .

16. The non-natural hybrid zinc finger polypeptide of any of the preceding claims, wherein the non-natural hybrid zinc finger comprises a first hybrid zinc finger domain as defined in any of the preceding claims 1-15.

17. The non-natural hybrid zinc finger polypeptide of any of the preceding claims, further comprising a second zinc finger domain, wherein the second zinc finger domain is a non-hybrid zinc finger domain, preferably selected from IKZF1 ZF3, IKZF3 ZF3, and ZFP91 ZF5, ZNF653 ZF5, ZNF276 ZF5 and / or ZNF827 ZF2, ZNF692 ZF5.

18. The non-natural hybrid zinc finger polypeptide of any one of the preceding claims, wherein the second zinc finger domain is C-terminal relative to the first hybrid zinc finger domain.

19. The non-natural hybrid zinc finger polypeptide of any of the preceding claims, wherein the second zinc finger domain is selected from IKZF1 ZF3, IKZF3 ZF3 and / or wherein the second zinc finger domain comprises an amino acid sequence according to SEQ ID NOs: 109-110.

20. A fusion protein comprising the degron tag of any one of claims 1-15 or the non-natural hybrid zinc finger polypeptide of any one of claims 16-19, wherein the fusion protein further comprises a protein of interest.

21. The fusion protein of any one of the preceding claims, wherein the degron tag or non-natural hybrid zinc finger polypeptide is located at the N-terminus or C-terminus of the target protein.

22. The fusion protein of any one of the preceding claims, wherein the target protein is selected from Cbl-b, SOCS1, CISH, Tox, Eomes, IL12, IL15.

23. A non-naturally occurring nucleic acid encoding the degron tag of any one of claims 1-15, the non-naturally occurring hybrid zinc finger polypeptide of any one of claims 16-19, or the fusion protein of any one of claims 20-22.

24. A vector comprising the non-naturally occurring nucleic acid of claim 23.

25. A cell or host cell expressing the non-naturally occurring nucleic acid of claim 24.

26. A method of providing a degron tag according to any one of claims 1 to 15, a non-natural hybrid zinc finger polypeptide according to any one of claims 16 to 19, a fusion protein according to any one of claims 20 to 22, or a nucleic acid encoding the same, the method comprising: (A) providing a hybrid zinc finger domain comprising a first portion and a second portion, wherein (4) The first part comprises the amino acid sequence X1X2C3X4X5C6X7X8X9X 10 X 11 , wherein X represents any amino acid of the first Cys2-His2 zinc finger domain; (5) The second part comprises the amino acid sequence X 12 X 13 X 14 X 15 X 16 X 17 X 18 H 19 X 20 X 21 X 22 H 23 , wherein X represents any amino acid of a second Cys2-His2 zinc finger domain, wherein the second Cys2-His2 zinc finger domain is different from the first Cys2-His2 zinc finger domain; (6) the second portion is C-terminal relative to the first portion; (B) introducing at least two different amino acid substitutions into the hybrid zinc finger domain, and wherein the substitutions are not in C3, C6, X7, H 19 or H 23 Any position in ; and (C) using the hybrid zinc finger domain obtained in step (B) or the nucleic acid sequence encoding the hybrid zinc finger domain obtained in step (B) to prepare the degradation determinant tag of any one of claims 1 to 15, the non-natural hybrid zinc finger polypeptide of any one of claims 16 to 19, the fusion protein of any one of claims 20 to 22, or the nucleic acid encoding these.

27. The method of claim 26, further comprising determining the sensitivity of the degradation determinant tag according to any one of claims 1-15, the non-natural hybrid zinc finger polypeptide according to any one of claims 16-19, the fusion protein according to any one of claims 20-22 for degradation induced by immunomodulatory imine drugs (IMiDs), preferably, wherein the IMiD is selected from thalidomide, lenalidomide, pomalidomide, avalidomide, ibolidomide, salts thereof and analogs thereof.

28. A method for degrading a target protein or for controlling the expression of a target protein, comprising contacting a cell with an effective amount of an IMiD in vitro or in vivo, wherein the cell expresses a nucleic acid encoding a degradation determinant tag according to any one of claims 1 to 15, a non-natural hybrid zinc finger polypeptide according to any one of claims 16 to 19, or / and a fusion protein according to any one of claims 20 to 22.

29. The method of claim 28, wherein the method is used to modulate the activity of a target protein.

30. A method for degrading a target protein or for controlling the expression of a target protein, comprising administering an effective amount of an IMiD to a subject, wherein the subject has previously been treated by gene therapy, causing at least some cells in the subject to express a nucleic acid encoding a degron tag according to any one of claims 1 to 15, a non-natural hybrid zinc finger polypeptide according to any one of claims 16 to 19, or a fusion protein according to any one of claims 20 to 22, wherein the fusion protein comprises the target protein.

31. The method of claim 31, wherein the gene therapy comprises introducing cells into the subject, wherein the introduced cells express a nucleic acid encoding the degron tag of any one of claims 1-15, the non-natural hybrid zinc finger polypeptide of any one of claims 16-19, or the fusion protein of any one of claims 20-22, wherein the fusion protein comprises a protein of interest.

32. Use of the degradation determinant tag of any one of claims 1-15, the non-natural hybrid zinc finger polypeptide of any one of claims 16-19, or the fusion protein of any one of claims 20-22, or a nucleic acid encoding any of these for controlling transcription factors such as Eomes, Tox, negative regulators of TCR signal transduction such as Cbl-b, negative regulators of cytokine receptors such as SOCS1, CISH, membrane-bound cytokines such as IL12, IL15, antigen receptors such as TCR, CAR, NKR, checkpoint receptors such as PD1, LAG3, TIM3, nucleases such as Cas9, TALEN or zinc finger nucleases.